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Summary 
Canonical WNT pathway regulates expression of target genes by modulating intracellular 
amount of β-catenin. Without WNT pathway activation, a so-called “destruction complex” 
including APC and Axin facilitates the degradation of β-catenin. Upon binding of WNT ligand 
to its receptor Frizzled, the destruction complex is antagonized and β-catenin is stabilized. 
Stabilized β-catenin goes to the nucleus, binds to the TCF/LEF family of transcription factors 
and initiates the new gene expression program.  
  
De-regulation of the WNT signaling pathway via mutations in APC and Axin, proteins that 
target β-catenin for destruction, or in β-catenin itself have been linked to various types of 
human cancer. These genetic alterations rarely, if ever, are observed in breast tumors. However, 
various lines of evidence suggest that WNT signaling may also be de-regulated in breast cancer. 
Most breast tumors show hypermethylation of the promoter region of secreted Frizzled-related 
protein 1 (sFRP1), a WNT antagonist, leading to downregulation of its expression. As a 
consequence WNT signaling is enhanced. We hypothesized that autocrine activation of WNT 
signaling plays an important role in breast cancer and loss of sFRP1 expression is one of the 
critical events leading to constitutively active WNT signaling in breast cancer formation.  
 
We show that de-regulation of the WNT signaling pathway appears to occur by autocrine 
mechanisms in a panel of breast cancer cell lines and that interference with WNT signaling in 
breast cancer cell lines reduces their proliferative ability. Furthermore, ectopic expression of 
sFRP1 suppresses autocrine WNT signaling in MDA-MB-231 human breast cancer cells and 
leads to dramatically impaired outgrowth of these cells as xenografts in nude mice. A 
microarray analysis led to the identification of two genes encoding CCND1 and CDKN1A whose 
expression level is selectively altered in sFRP1 expressing tumors. The corresponding proteins, 
cyclin D1 and p21Cip1 were down- and up-regulated, respectively in sFRP1 expressing tumors, 
suggesting that they are downstream mediators of WNT signaling. In addition to the effect on 
cell proliferation, we show that WNT stimulates the migratory ability of T47D human breast 
cancer cells. Conversely, ectopic expression of sFRP1 decreases the migratory potential of 
MDA-MB231 cells, suggesting that WNT activation not only promotes cell growth, but also 
stimulates cell motility.  
 
In summary, these results suggest that the WNT pathway has an impact on various biological 
characteristics of human breast cancer cell lines. Throughout these studies, we revealed the 
possibility that interference with WNT signaling at the ligand-receptor level is a valid therapeutic 
approach in breast cancer.   
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I. INTRODUCTION 
 
1. Breast cancer 
1.1. Normal female breast  
1.1.1. Anatomy of normal female breast    
Mammalian females in general have modified skin appendages that provide complete nourishment 
and immunologic protection for the newborns. In humans, paired mammary glands rest on the 
pectoralis muscle on the upper chest wall. The breast is composed of specialized epithelium and 
stroma. Six to ten major ductal systems originate at the nipple. The duct is lined by a double-layered 
epithelium. Although the breast ductal system is comprised of domains with distinct morphology 
and function, this layered architecture is found throughout the mammary gland from the nipple to 
the terminal alveoli. Successive branching of the large ducts eventually leads to the terminal duct 
lobular unit (TDLU). In the adult woman, the terminal duct branches into a grapelike cluster to form 
a lobule (Fig.1).  
 
In the normal breast, ducts and lobules are lined by two cell types, myoepithelial cell and luminal 
cells. The mypepithelial cell is a contractile cell containing myofilaments and it is a component of a 
low, flattened discontinuous layer lying on the basement membrane. It assists milk ejection during 
lactation and has an important role in maintenance of the normal structure and function of the lobule 
and the basement membrane [1]. Luminal cells are components of the second (inner) layer of 
epithelial cells which line the lumens. Only the luminal cells of the terminal duct and the lobule 
produce milk, while those lining the large duct system do not produce milk. A committed stem cell 
in the terminal duct gives rise to both luminal and myoepithelial cells [2]. 
In humans, the majority of breast stroma consists of fibrous connective tissue mixed with adipose 
tissue (interlobular stroma). Lobules are enclosed by a breast-specific hormonally responsive stroma 
that contains a scattering of lymphocytes (intralobular stroma). 
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Figure 1. Anatomy of human female breast  
Left: Sagittal section of human adult breast and illustration of the TDLU 
Right: Structure of the breast lobule 
Double-layered cuboidal epithelium, luminal cell and myoepithelial cell are surrounding the lumen. 
This epithelial sheet is sequestered from stroma by basement membrane. 
 
 
Left: Tabár 1998 
Right: Mammographic Imaging, 2nd Edition 
 
 
1.1.2. Life cycle changes    
The breast is not fully formed at birth, undergoes cyclic changes during the life span in which a 
female has menstruation, undergoes full differentiation when a female gives a birth, and starts to 
involute long before menopause. 
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During mid-embryogenesis, the specialized mesenchyme of the breast fat pad condenses around the 
epithelium of the breast bud. Via a complex interaction between stromal and epithelial cells, cords 
of cells "invade" the stroma to form the elementary ductal system. The continuing cross-talk 
between epithelium and stroma promotes normal tissue structure and function throughout life. The 
prepubertal breast has a minimal lobule formation. At the beginning of menarche in women, the 
terminal ducts give rise to lobules, and the interlobular stroma increases in volume. However, there 
is not yet much adipose tissue at that time. 
  
The breast changes during the menstrual cycle [3]. In the first half of the cycle, which is called the 
follicular phase, the lobules are relatively quiescent. After ovulation, under the influence of estrogen 
and rising progesterone levels, cell proliferation and the number of acini per lobule increase, and 
vacuolization of epithelial cells occurs. Intralobular stroma markedly swells. When menstruation 
occurs, estrogen and progesterone levels fall, leading to epithelial cell apoptosis, disappearance of 
the stromal edema, and overall regression in the size of the lobules. 
 
It is only with the onset of pregnancy that the breast completes morphologic maturation and 
functional activity. Lobules increase both in number and in size. As a consequence, by the end of 
the pregnancy, the breast is composed almost entirely of lobules separated by a relatively small 
amount of stroma. By the third trimester, secretory vacuoles of lipid material are found within the 
epithelial cells of the TDLU, but milk production is inhibited by the high levels of progesterone. 
Immediately after birth, the breast produces colostrum (high in protein), which changes to milk 
(higher in fat and calories) within the first 10 days as progesterone levels drop. Breast milk not only 
provides complete nourishment, but also provides maternal antibodies (mainly IgA), cells 
(neutrophils, lymphocytes, and macrophages), and other proteins (e.g., cytokines, fibronectin, and 
lysozyme) to protect the infant against infection and allergies [4] [5]. 
 
1.2. Carcinoma of the breast 
Around 80% of cancer-related deaths in the Western world are due to carcinoma, which arises from 
epithelia. Breast cancer is not the exception since most breast tumors arise from epithelia. Among 
them, the majority of human breast cancers arise from the TDLU and not from the ductal system [6]. 
Here, as I write about breast cancer, I start with describing the etiology and pathogenesis, in order to 
make it easy to understand the mechanism underlying breast cancer development.   
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1.2.1. Etiology and pathogenesis 
1.2.1.1. Risk factors of breast cancer 
Carcinoma is the most common malignancy of the breast. A woman who lives to age 90 has a one 
in eight chance of developing breast cancer. Because of the frequency of this disease in women, 
extensive studies on risk factors for developing breast cancer have been made. 
Four of the most common risk factors for the development of breast cancer are, age, age at 
menarche, first live birth and first-degree relatives. Age is a risk factor common with almost all 
types of cancers, because long life itself accumulates not only DNA damages, but also the other risk 
factors. On the other hand, age at menarche and first live birth are risk factors remarkable for breast 
cancer.  
 
The younger a woman’s age at menarche, the higher her risk to suffer from breast cancer [7]. 
Women who reach menarche at 12 years old or younger have 23% increased risk of developing 
breast tumor compared to women who reach menarche after 15 years old [8] (table 1). Late 
menopause also increases the risk. For every 5-year difference in age at menopause, the risk for 
breast cancer changes by about 17% [9]. There is also a report showing that women who reach 
natural menopause after age 55 have double of the risk of developing breast tumor compared to 
women who reach natural menopause before age 45 [10] (table 2). However, among 
postmenopausal women, the increased risk associated with late age at natural menopause is 
generally not seen until age 65, suggesting that the effect of age at menopause is not seen for 10-20 
years after menopause [11]. The increased risks associated with early menarche and late menopause 
suggest that the longer the exposure to sex hormones through a woman’s life, the higher the risk of 
breast cancer [12] 
.  
Another risk factor is age at first pregnancy. The younger a woman is when she has her first 
full-term pregnancy, the lower her risk of developing breast cancer [7]. Women with a first full-term 
pregnancy at younger than 20 years old have half the risk of women who do not give birth all 
through their life or women with a first full-term pregnancy at age of over 35 [13] (table 3). It is 
hypothesized that pregnancy results in terminal differentiation of epithelial cells, removing them 
from the potential pool of cancer precursors. However, the biologic basis of such differentiation has 
not been determined. 
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The risk of breast cancer also increases with the number of affected first degree relatives (mother, 
daughter or sister). However, not a majority of women suffering from breast cancer have such 
backgrounds. Only 13% of women with breast cancer have one affected first-degree relative, and 
only 1% have two or more affected first-degree relatives. This means that around 87% of women 
with a family history will not develop breast cancer [14].  
 
 
 
 
Table 1-3 
Relation between risk of developing 
breast tumor and age at menarche, 
natural menopause and first full term 
pregnancy 
 
Reviewed by Jennifer L. Kelsey et al. 1993 
 
 
1.2.1.2. Molecular alterations in breast cancer 
Breast cancer is remarkable for its heterogeneity and currently it is not possible to provide a full list 
of all potential molecular alterations causing breast cancer. However, some are well known. Among 
them, here, I start with describing the tumor suppressor genes, BRCA1 and BRCA2, molecules 
altered in breast cancer, because mutation in BRCA1 and/or BRCA2 is the most common event 
occurring in familial breast cancer patients. Then I will mention about estrogen receptor and 
ErbB2/HER2 receptor as most notable molecules altered in sporadic breast cancers. In fact, 
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estrogen receptor positive breast cancer and ErbB2/HER2 overexpressing breast cancer account for 
a large portion of all breast cancers, 70% and 20% respectively. Furthermore, currently breast 
cancer is roughly classified into three subgroups for clinical reason, estrogen/progesterone receptor 
positive, ErbB2/HER2 receptor overexpressing, and the others.  
 
1.2.1.2.1. BRCA1 and BRCA2 
About 25% of familial breast cancers, meaning around 2-3% of all breast cancers, can be attributed 
to two autosomal genes, BRCA1 and BRCA2 [14]. BRCA1 and BRCA2 act as tumor suppressors. 
The probability of breast cancer is associated with a mutation in these genes.  
 
BRCA1 and BRCA2 do not show sequence homology, however, they function in similar pathways 
and interact with the same multi protein complexes. A wide variety of functions have been 
suggested for these proteins, including transcriptional regulation, cell-cycle control, 
ubiquitin-mediated protein degradation pathways, and chromatin remodeling. 
 
A key function for both BRCA1 and BRCA2 appears to be their role in protecting the genome from 
damage by halting the cell cycle and promoting DNA damage repair in a complex process that is 
not yet fully understood. BRCA1 is phosphorylated in response to DNA damage and may transduce 
DNA damage signals from checkpoint kinases to effector proteins [15]. BRCA2 can bind directly to 
DNA and function in homologous recombination, which ensures the error-free repair of double 
strand DNA breaks [16]. 
 
Studies have shown that mutations of the BRCA1 and BRCA2 genes increase the risk of early onset 
breast carcinoma. BRCA1 mutation carriers have an 18% risk and BRCA2 mutation carriers have a 
15% risk for developing breast cancer before the age of 39 years, and the risk increases to 59% for 
BRCA1 mutation carriers and 34% for BRCA2 mutation carriers at ages 40–49 years old[17] [18]. 
In hereditary carcinomas, one mutant BRCA allele is inherited, and the second allele is inactivated 
by somatic mutation. Although BRCA1 and BRCA2 mutations are rarely if ever found in sporadic 
tumors, about 50% of such tumors have decreased or absent expression of BRCA1. In most cases, 
this is accomplished by a combination of loss of heterozygosity (LOH) and methylation of the 
promoter to inactivate both alleles [19].  
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BRCA1-associated breast cancers are more commonly poorly differentiated compared to sporadic 
breast carcinomas and do not express hormone receptors or overexpress ErbB2/HER2 receptor, 
while BRCA2-associated breast carcinomas do not have a distinct morphologic appearance [20] [21] 
[22]. Most BRCA1-associated breast carcinomas are characterized by the expression of basal 
(myoepithelial) markers, such as cytokeratin 5/6 and or P-cadherin. Furthermore, RNA profiling has 
revealed that BRCA1, BRCA2, and subtypes of sporadic cancers can be recognized by their gene 
expression patterns [23] [24]. The mRNA profile of BRCA1-associated breast carcinoma is similar 
to a type of sporadic carcinomas termed “basal-like” carcinomas. These results suggest that a subset 
of sporadic carcinomas have biologic similarities to hereditary carcinomas [22].  
 
1.2.1.2.2. Estrogen and ER 
Approximately and 70-80% of sporadic breast carcinoma express estrogen receptor (ER) [25-27]. In 
normal breast, estrogen plays a role in the growth of mammary gland in females and it lasts till the 
menopause, however, many evidences support the hypothesis that cumulative and/or excessive 
exposure to endogenous estrogen across a woman’s life span contributes to and may be a causal 
factor in breast cancer [28]. 
Estrogen is a general term for a group of steroid sex hormone which is mainly secreted from ovary. 
The major members of estrogen are estrone (E1), estradiol (17β-estradiol, E2) and estriol (E3). 
Estrogens are naturally occurring cyclopentanophenanthrene compounds whose synthesis begins 
with cholesterol. While all E1, E2 and E3 can bind estrogen receptor (ER), the most potent and 
dominant estrogen is E2. 
 
Estrogens can function via multiple mechanisms (Fig.2) [28]. The classic mechanism is the binding 
of the estrogens to nuclear ERs. Then the estrogen-ER complexes bind as dimers to 
estrogen-response elements (EREs) in the regulatory regions of estrogen-responsive genes and 
associate with basal transcription factors, co-activators and co-repressors to alter gene expression. 
For example, E2 and ER complex can mediate the activation of proto-oncogenes and oncogenes 
(e.g. c-fos, c-myc), nuclear proteins, as well as other target genes and eventually drive the 
proliferation of premalignant lesions as well as cancers [29, 30]. Non-classical mechanism involves 
ER-mediated gene expression without direct binding to DNA but through modulation of 
protein-protein interactions with other DNA-binding transcription factors [31]. Like peptide growth 
factors, estrogen can also exert non-genomic actions that are too rapid to be accounted for by gene 
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transcription and RNA and protein synthesis. For this, membrane-bound ERs play roles. Binding of 
estrogens to membrane-bound form of ERs leads to activation of various protein kinases [32] [33] 
(Fig.2). Reported nongenomic effects of 17β-estradiol include direct or indirect activation of 
adenylate cyclase and production of cyclic AMP, MAPK, Akt, Src, Shc, the regulatory and 
endothelial nitric oxide synthase (eNOS), amoung otheres [34]. There are also cross-talks between 
the membrane ER signaling process and other signaling pathways, such as epidermal growth factor 
receptor and insulin-like growth factor 1 receptor signaling pathways [28]. Recent study also 
showed the presence of ERs in mitochondria of various cells and tissues. The mitochondrial 
genome contains potentially estrogen-responsive sequences and estrogen has increased 
mitochondrial DNA-encoded gene transcript levels [28]. Finally, amplified growth factor receptor 
signaling can post-translationally modify the ER and its coactivators, resulting in 
estrogen-independent transcriptional activity of ER at EREs [35].  
Besides these effects of estrogen on intracellular signaling and/or gene translation, estrogen itself 
can cause DNA damage phisically. Metabolites of estrogen can cause mutations or generate 
DNA-damaging free radicals [36] [28].  
 
ERs have been initially identified as ligand-activated transcription factors that belong to the nuclear 
hormone receptor super family. Today, the two receptors are known as ERα and ERβ. They are 
products of two distinct genes. However, they are highly similar to each other when compared at the 
amino acid level. The amino acid sequence identity between ERα and ERβ is approximately 97% in 
the DNA-binding domain and approximately 56% in the ligand-binding domain, whereas the N 
terminus is poorly homologous at 24% [37]. In breast, ERα is found in the ductal and lobular 
epithelial cells, but not in stroma [38]. On the other hand, ERβ is found in both ductal and lobular 
epithelial and stromal cells of the rodent [38]. The functional difference between ERα and ERβ has 
not yet been clearly understood. 
 
Although currently only the ERα form is clinically measured for clinical decision-making and 
treatment, various ER transcripts have been found in breast carcinomas [38]. Protein products 
corresponding to variant ERs have been described previously [39]. Normal and cancer tissues 
display a variety of distinct profiles regarding ERα, ERβ, and splice variants at both mRNA and 
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protein levels [39]. This heterogeneity in ER isoform profiles is suggested to result in variations in 
estrogen signaling and might affect breast cancer risk, hormone responsiveness, and survival.  
 
Currently, Tamoxifen and similar antiestrogens inhibitors are the first-line therapy for treatment of 
hormone-dependent breast cancer [40]. However, further study to understand the heterogeneous 
estrogen-ER complex function is needed to develop more efficient treatment for ER positive breast 
cancer patients.  
 
 
 
Figure 2. Estrogen-receptor-signaling pathways      Reviewed by James D.Yager et al. 2006 
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1.2.1.2.3. ErbB2 receptor 
In 1983, v-erbB was first cloned from avian eythroblastic leukemia virus [41] and in the next year, 
it was suggested that v-erbB was oncogenic form of the proto-oncogene coding EGFR [42]. Two 
years after the cloning of v-erbB, a gene coding tyrosine kinase receptor which also has a high 
homology to the gene coding human EGFR was cloned. The product of this gene was named HER2, 
an abbreviation of “human EGFR-related 2”. At the same time, HER2 was found to be the same 
molecule coded by the oncogene, neu which had been found in rat neuroglioblastoma [43]. And 
around the same time, another group reported that a gene which has homology to v-erbB was 
amplified in human breast cancer cells [44]. This gene also had high homology to the gene coding 
human EGFR, but not the same gene. Then this new gene was named c-erbB2, while the gene 
coding human EGFR was named c-erbB1. Eventually, neu and c-erbB2 were found to be the same 
gene [45]. This was the first report showing the relation between ErbB2/HER2 and breast 
carcinoma. 
  
After these findings, a lot of researches on ErbB/EGFR have been made. Today, it is known that the 
ErbB family consists of four family members, EGFR/ErbB1/HER1, ErbB2/Neu/HER2, 
ErbB3/HER3 and ErbB4/HER4. Homology between the molecules of this family is around 70-80%. 
All members have an extracellular ligand-binding region, a single membrane-spanning region and a 
cytoplasmic tyrosine-kinase-containing domain. All of these family members, except for erbB2 
have their corresponding ligands. Binding of these ligands to each ErbB receptor leads to homo- or 
hetero-dimerization of the receptors and activation of their intracellular kinase domains. There are 
altogether 10 reported ligands. EGF, TGF-α, and amphiregulin (AR) bind specifically to ErbB1. 
Betacellulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR) bind to ErbB1 and 
ErbB4. Neuregulin1 (NRG1) and neuregulin2 (NRG2) bind to ErbB3 and ErbB4. Neuregulin3 
(NRG3) and neuregulin4 (NRG4) bind to ErbB4 (Fig.3). 
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Figure 3. ErbB receptors and ligands      Reviewed by Hynes, NE. and Lane, H. 2005 
 
 
Structural studies suggest that biding of these ligands to ErbB receptor changes the conformation of 
the receptor so that the protruding arm from the extracellular domain of the erbB receptor becomes 
“opened-form”. This protruded structure provides a direct receptor-receptor interaction. Because of 
this unique mechanism to form a receptor dimer, the two ligands are distant from each other even 
after dimerization [46] [47]. Although there are no reported soluble ligands which bind to ErbB2, 
ErbB2 can form heteromeric complexes with ErbB1, ErbB3, or ErbB4. This can be explained by the 
conformation of ErbB2. Even without ligand binding, ErbB2 shows “opened-form” of the 
extracellular protruded arm which provides a direct receptor-receptor interaction. The structure of 
ErbB2 is similar to that of the EGFR when it binds with its ligand [48]. Because of this structural 
reason, ErbB2 can form heterodimers with the other ErbB members without ligand binding. 
 
Upon the dimerization of ErbB receptors, the intracellular kinase domains of the receptors get 
activated and signals are transferred to various intracellular signaling pathways via phosphorylation. 
The only exception, ErbB3 has impaired kinase activity and only acquires signaling potential when 
it is dimerized with another ErbB receptor and phosphorylated. Downstream process of ErbB 
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signaling is very complex. However, the two main pathways downstream of ErbB receptors are 
mitogen-activated protein kinase (MAPK) pathway and phosphatidylinosithol-3-kinase (PI-3K) 
pathway. Shc- and/or Grb2-activated MAPK pathway is a common target of all ErbB receptors [49]. 
Similarly, the PI-3K pathway is directly or indirectly activated by most ErbBs, but mainly due to 
ErbB3 [50]. 
 
Among all ErbB receptors, ErbB2 has very strong kinase activity [51] and notably, around 25% of 
breast tumor overexpress ErbB2 [52]. This overexpression of ErbB2 in breast tumor is mainly 
caused by gene amplification or by hyper-activated gene transcription. Furthermore, ErbB2 
overexpression is associated with increased tumor aggressiveness, increased rates of recurrence, and 
increased mortality [53] [54]. Although mutations in kinase domain of ErbB2 were identified in a 
small subset of non-small cell lung cancer and subsequently in other tumor types including head 
and neck, ovarian, brain and gastric cancers [55] [56], no activating alterations of the c-erbB2 gene 
have been found in human breast tumors [57]. ErbB2/ErbB3 heterodimer is reported to have the 
strongest signal transduction ability among all the homo- and heterodimers of ErbB receptor family 
members [51]. Besides the complex with ErbB3, the overexpression of ErbB2 also induces 
spontaneous receptor dimerization without the need of ligands. ErbB2/ErbB3 heterodimers and 
ErbB2/ErbB2 homodimers or higher order complexes are considered to play important roles in 
breast cancer progression. 
 
Upon ErbB2 activation, signaling molecules are recruited to phosphorylated tyrosine residues 
triggering intracellular signaling cascades such as the Ras/Erk and PI3K/Akt pathways (Fig4-a). In 
addition to this classical route, although it is not so well accepted, ErbB2 was also shown to 
translocate to the nucleus and associate with specific sequences within the promoter region of 
proto-oncogenic genes to regulate their expression (Fig4-b) and furthermore, ErbB2 was 
demonstrated to control expression of specific proteins at the level of translation, via the Akt/mTOR 
pathway (Fig.4-c) [56]. Much more research should be made on the signaling pathways downstream 
of ErbB2 to understand the mechanism of tumorigenesis, however, it is clear that ErbB2 receptor 
signaling should be one of the most potent targets to treat breast cancer patients.   
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Figure 4. ErbB2-induced intracellular signaling pathways Reviewed by Badache, A. et al. 2006 
 
 
In 1985, it was shown that the transformed phenotype of neu-transformed NIH3T3 cells is reverted 
to an untransformed phenotype by anti-neu antibody treatment [58]. This report prompted 
researchers to develop an antibody against human erbB2 for the use of breast cancer therapy. As a 
result of researchers’ efforts, trastuzumab (Herceptin) has been developed and currently it is used to 
target ErbB2 in ErbB2 overexpressing breast cancer patients. Trastuzumab is a recombinant 
humanized monoclonal antibody directed against the extracellular domain of ErbB2. Although 
trastuzumab treatment is efficient in clinical studies, the mechanisms by which trastuzumab exert 
the effect on ErbB-overexpressing tumors are not fully understood.  Initially, it was thought that 
upon the binding with trastuzumab, ErbB2 receptor is internalized and degraded. However, while 
ErbB2 down-modulation has long been considered as the primary event of trastuzumab inhibitory 
effect, some studies examining ErbB2 localization and trafficking suggest that trastuzumab does not 
actually down-modulate ErbB2 [59]. Thus this “ErbB2 internalization hypothesis” is not 
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satisfactory. On the other hand, another hypothesis is that after the binding with ErbB2, the Fc 
domain of trastuzumab triggers antibody dependent cellular cytotoxicity (ADCC). As another 
hypothesis, although this hypothesis is currently not well accepted, in 2004, it was reported that 
trastuzumab activates tumor suppressor protein, PTEN, resulting in the suppression of PI3-K [60]. 
PTEN binds to the plasma membrane via the C2 domain that is negatively regulated by 
Src-dependent tyrosine phosphorylation. Trastuzumab is hypothesized to interfere with the 
association of ErbB2 and Src, resulting in the inhibition of Src activation. If Src is not activated, 
PTEN is not phosphorylated. Without tyrosine phosphorylation, PTEN can go to the plasma 
membrane and there dephosphorylate PIP3, leading to the inhibition of the activation of AKT 
(PKB) [61]. These hypotheses are still under discussion and further research is necessary for the 
efficient use of trastuzumab treatment.  
  
1.2.2. Classification of breast carcinoma 
Breast cancer is remarkable for its heterogeneity and further investigation will need to answer the 
question, “how heterogeneous it is”. As a simple example, in normal human mammary grand, there 
are two distinct types of epithelial cell, luminal epithelial cells and basal (and/or myoepithelial) 
cells. These two cell types can be distinguished immunohistochemically by detecting the expression 
of specific keratins. Luminal epithelial cells can be stained with antibodies against keratin 8/18 [62], 
on the other hand, basal epithelial calls can be stained with antibodies against keratin 5/17 [63]. 
Character of a breast cancer, indeed, seems to differ depending on which lineage a breast cancer 
arise from. Furthermore, in addition to this histology-based classification, at the clinical level, 
breast carcinoma has been roughly categorized according to the status of estrogen receptor (ER), 
progesterone receptor (PgR), and ErbB2/HER2 receptor for clinical decision-making and treatment.  
 
ER status is measured as a prognostic factor and a means to predict response to endocrine 
(anti-estrogen) therapy. PgR is an ER-regulated protein and the presence of PgR should indicate a 
functional ER pathway. In fact, the presence of PgR was associated with better response to 
endocrine therapy in some studies [64] [65] [66]. On the other hand, overexpressed ErbB2/HER2 in 
tumor tissue suggests a good response to therapies targeting the pathway activated by ErbB2/HER2, 
for example, treatment with trastuzumab (Herceptin). 
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However, not all the ER+/PgR+ breast carcinomas react to hormonal treatments and also not all 
HER2 overexpressing breast tumor is cured by trastuzumab treatment. Furthermore, 10-15% of 
breast cancers are neither ER/PgR positive nor overexpressing HER2. These remaining breast 
cancers are in a so-called “triple-negative” (also called “receptor-negative”) category [67]. Breast 
cancer in this category is not treated with therapy targeted to ER or ErbB2 signaling. The lack of 
targets prompted researchers to find more precise classification of breast cancer in order to target 
candidate pathways to develop efficient treatment for individual breast cancer patients. 
 
In 2000, Perou and co-workers showed the possibility to classify breast cancers based on gene 
expression profiles using DNA microarray technology [68]. Within a couple of years after this 
report, the same group reconfirmed the robustness of this DNA microarray-based classification and 
showed that there are at least 5 subtypes of breast cancer based on gene expression profiles, 
Luminal A, Luminal B, Basal-like, ERBB2+, and Normal Breast-like subtypes [69, 70].  
 
Luminal subtypes are ER positive and characterized by the relatively high expression of many 
genes expressed by breast luminal cells including keratin 8/18. Within the luminal subtypes, 
luminal A shows the highest expression of the ERα gene, on the other hand, luminal B shows low 
to moderate expression of the luminal specific genes including the ER cluster.  The other groups 
are all characterized by low to absent gene expression of the ER and several additional 
transcriptional factors expressed in the luminal/ER+ cluster. The basal-like subtype is characterized 
by high expression of keratins 5 and 17, laminin and fatty acid binding protein 7. Because of the 
expression of the basal keratins 5 and 17, this group is called “basal-like”. ErbB2+ subtype is 
characterized by high expression of several genes in the ERBB2 amplicon at 17q22.24 including 
ERBB2 and GRB7, suggesting that a potent mechanism of overexpressing ErbB2 in breast cancer is 
gene amplification. Normal breast-like group shows the highest expression of many genes known to 
be expressed by adipose tissue and other nonepithelial cell types and also shows strong expression 
of basal epithelial genes and low expression of luminal epithelial genes[68] [69].  
 
This method to classify breast cancer subtype according to DNA expression profile brought us new 
aspects of breast cancer classification. The proportion of each subtype in all breast cancer cases are 
calculated and shown on table 4 [70]. Three independent studies show almost same distribution of 
the five novel breast cancer subtypes. The prognoses for each subtype are also distinctive. The 
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prognosis is the best for luminal A breast cancer, on the other hand, basal-like breast cancer has the 
worst prognosis (Fig.5).   
 
 
 
Table 4. Distribution of tumors (%) from three different studies across five tumor subtypes     
Sorlie, T. et al. 2003 
 
  
Figure 5. Prognoses of different subtypes of breast cancer    Sorlie, T. et al. 2003 
(Data was obtained without Herceptin treatment) 
 
Interestingly, Carcinomas arising in women with BRCA1 mutations also cluster with basal-like 
group. BRCA1 carcinomas are similar to basal-like carcinomas in being poorly differentiated, 
lacking ER and HER2/neu expression, and expressing basal-like keratins. However, most women 
with basal-like carcinomas do not have germ-line BRCA1 mutations [70] [67].  
 
Currently, there are no treatment targeting basal-like breast cancer and it has the worst prognosis as 
described above. There are still many things to be uncovered in order to find a good strategy to treat 
basal-like breast cancer, however, the character of basal-like breast cancer is still largely unknown. 
For example, we do not have a clear answer even to the simple question, “where does basal-like 
breast cancer come from?” First of all, in the breast, the term “basal” has acquired two meanings. In 
one context it has become the word having the same meaning of “breast myoepithelium” and in the 
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other context, it defines a specific subpopulation of “basal” cytokeratins, CK5, CK14 and CK17, 
expressing cells [6]. However, in the latter meaning, the origin of “basal” cell is still controversial. 
Because most basal-like breast tumors still express luminal cytokeratin 8/18, suggesting that 
basal-like cancers also possess characteristics of luminal lineage. Furthermore, several classic 
myoepithelial markers were rarely expressed in basal-like tumors. These findings provide evidence 
against the hypothesis that basal-like breast cancers are derived directly from myoepithelial cells. 
Instead, these finding could suggest the possibility that basal-like breast cancer cells is 
differentiated directly from a stem cell [67]. This hypothesis is currently still under the discussion, 
however, further study on this hypothesis might bring a breakthrough to target basal-like breast 
cancer.   
  
1.2.3. Breast cancer research Model 
1.2.3.1. Breast cancer cell lines 
Breast cancer cell lines have been the most widely used models to investigate how proliferation, 
apoptosis and migration become deregulated during the progression of breast cancer. Established 
cell lines are easily propagated, relatively easy to manipulate genetically, and generally yield 
reproducible results under well-defined experimental conditions. Compared to rodent cells, human 
cells are more frequently used. The main reason for this is, first of all, human cells have more 
relevance to human disease. Furthermore, it has been suggested that same genetic alterations might 
not transform both mouse and human epithelial cells [71]. Various breast cancer cell lines are used 
for breast cancer research. One of the most comprehensive studies on these breast cancer cell lines 
is the report by Neve R. M. and his colleagues [72]. There, cells are characterized according to their 
ER, PgR, HER2, and TP53 (p53) status.    
 
1.2.3.2. Mouse models 
The growth of breast cancer cell lines as xenografts makes it possible to investigate the breast 
cancer growth and progression in the in vivo environment, which includes the complex 
tumor-stromal cell interactions that facilitate tumor formation and progression. As 
immunocompromised mouse experimental model, nude mice and SCID mice are widely used.  
 
The nude mouse has been a major breakthrough for cancer research because it allows human tumors 
to be studied in another animal. The nude mice were discovered in 1962 as a hairless mutant. They 
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have a spontaneous deletion in the nu (FOXN1) gene on the chromosome 11. As a result, the nude 
mouse lacks or has a deteriorated thymus and also does not have hair. Because they lack thymus, 
nude mice cannot generate mature T lymphocytes. Therefore, they are unable to mount most types 
of acquired immune responses including antibody formation that requires CD4+ helper T cells, 
cell-mediated immune responses which require CD4+ and/or CD8+ T cells, delayed-type 
hypersensitivity responses which require CD4+ T cells, killing of virus-infected or malignant cells 
which requires CD8+ cytotoxic T cells, and graft rejection which requires CD4+ ad CD 8+ T cells. 
 
SCID mice were discovered in 1983. These mice were suffering severe combined immune 
deficiency (SCID). They have a mutation in the gene, scid (Prkdc), which is located on the 
chromosome 16. Because of this mutation, SCID mice can not complete the rearrangement of genes 
coding IgG and T cell receptor during lymphoid maturation. This leads to the lack of both B cells 
and T cells in SCID mice. Thus, SCID mice are even more immunodeficient than nude mice, which 
lack only T cells.  
 
Experiments using these mice have brought us a lot of useful knowledge about breast cancer, 
however, there are some technical aspects that affect the utility of xenograft models. The most 
important one is that xenografts must be established in immunocompromised mice as described 
above. The absence of an intact immune system in xenograft experiments may profoundly affect 
tumor development and progression.  
 
2. WNT signaling 
2.1. Discovery of Wnt1 
The research on WNT signaling had started more than 30 years ago. In early-mid ‘70s, a 
Drosophila mutant which lacks wing was found. This mutant fly embryo showed severely impaired 
segmentation of the epidermis as evidenced by abnormalities in the overlying ventral cuticle. In 
contrast to the wild-type cuticle, which exhibits alternating denticle and naked belts, the mutant 
cuticle was completely covered with denticles. These phenotypes were caused by a mutation which 
inactivates a segment polarity gene, which is in general responsible for specifying anterior posterior 
polarity within individual embryonic segments. The gene responsible for the phenotype of the 
mutant fly was named “wingless (Wg)” [73] [74].  
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On the other hand, an oncogene which causes mouse mammary tumors was identified through the 
research on mouse mammary tumor virus (MMTV). It is known that the majority of mammary 
tumors in mice are caused by MMTV. MMTV is a retrovirus which can be transmitted 
endogenously or vertically via milk. It does not code an oncogene itself, however, when the virus 
RNA is reversely transcribed into DNA and inserted inside or near an oncogene of host genome, the 
expression of the oncogene can be changed and cause a cancer [75]. During the study on MMTV, in 
1982, a mouse gene that is induced by (MMTV) was identified and referred as “int-1’ [76]. 
 
These two independent studies unexpectedly met each other in 1987. Rijsewijk and colleagues 
isolated the Drosophila homolog of Int-1, Dint-1. And found that Dint-1 and the segment polarity 
gene wingless are identical and map to the same location [77]. Then this protein started to be called 
as “Wnt-1” (Wingless + int-1). Now it is known that Wnt1 is a modified glycoprotein which is 
secreted from expressing cells. 
 
2.2. Pathway background 
Biochemical properties of Wnt proteins, ligands in Wnt signaling, and receptors in Wnt signaling 
are well summarized in the review by Kikuchi and his colleagues [78] and the phenotypes of 
Wnt-related gene knockout mice are well summarized in the review by Amerongen and Berns [79]. 
 
2.2.1. WNT ligands 
WNT family are secreted, glycosylated and palmitoylated peptides that interact with 
seven-transmembrane receptors of the Frizzled (FZD) family [80]. The primary amino-acid 
sequence of Wnts suggests that they should be quite soluble. However secreted Wnt proteins are 
hydrophobic and are mostly found associated with cell membranes and the extracellular matrix 
(ECM) [81]. After the purification of active Wnt proteins, mass spectroscopy analyses revealed that 
Wnt proteins are lipid modified by the attachment of a palmitate moiety on the first absolutely 
conserved cysteine residue within the protein family [82]. It was shown that Wnt proteins are 
palmitoylated by the acyltransferase named porcupine and anchored to the membrane of ER [83]. 
This step is suggested to be critical, because Wnt secretion is completely abrogated in the absence 
of porcupine [84]. Then ER-anchored Wnt proteins are glycosylated and transported to the cell 
membrane to be secreted [85].  
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The hydrophobic character of Wnts strengthens their interaction with the cell membrane and 
extracellular matrix, favoring short-range autocrine and juxtacrine signaling [84]. A number of 
diverse signaling pathways are activated upon WNT/FZD binding. Genome sequencing has 
revealed that mammalian species have roughly 20 (human has 19) secreted Wnt proteins, which can 
be divided into 12 conserved Wnt subfamilies (Fig.6) [86]. Each human Wnt gene exists on an 
independent gene locus, however, some of the members are located close to each other. Namely, 
Wnt3and Wnt9b are on 17q21, Wnt3a and Wnt9a are on 1q42, Wnt2 and Wnt16 are on 7q31, Wnt1 
and Wnt10b are on 12q13, Wnt6 and Wnt10a are on 2q35. Among them, notably, Wnt1 and Wnt10b, 
and Wnt6 and Wnt10a are very close to each other and the expression of these closely-located genes 
might be regulated in harmony.  
 
2.2.2. WNT receptors 
Frizzled (FZD) receptors 
Wnt ligands interact with the cell surface receptor, Frizzled (FZD). FZD receptors are seven-pass 
transmembrane receptors which have cycteine-rich domains (CRD) in their N-terminus. Through 
the CRD, FZD receptor binds Wnt ligands [87]. In general, it is thought that a monomeric FZD 
receptor transmit signals downstream upon binding with Wnt ligand, however, the crystallographic 
resolution of the structure of the mouse FZD8 and sFRP3 CRD domains suggested that CRDs might 
be able to homodimerise or heterodimerise [87]. Furthermore, there are reports showing that 
dimerisation of FZD receptor activates the Wnt/β-catenin pathway [88] and that FZD form specific 
homo- and hetro-oligomers [89]. These reports suggest the wide possibility of the signal 
transmission mechanism downstream of FZD receptor.  
Upon the binding of Wnt to FZD receptor, the intracellular amino sequences, K-T-X-X-X-W 
directly binds to Dishevelled proteins [90]. There are 10 reported human frizzled receptors. 
Phylogenetically, the Frizzled receptors fall into four groups. Frizzled-1, 2 and 7, and Frizzled-3 and 
6 make up two related groups, while Frizzled-5 and 8 comprise a third group, and Frizzled-4, 9 and 
10 generate a distant fourth group [91]. 
 
LRP5, LRP6 
There also exist co-receptors of FZD receptor. A genetic study using flies showed that a single-pass 
trans-membrane receptor, Arrow, is required to establish a segment polarity triggered by Wg 
signaling [92]. Arrow is homologous to two members of the mammalian low-density lipoprotein 
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receptor (LDLR)-related protein (LRP) family, LRP5 and LRP6. LRP5/6 function as co-receptors of 
FZD receptor and binding of Wnt ligand to both FRZ receptor and LRP5/6 co-receptor activates 
Wnt/β-catenin pathdway [93].  
 
Kremen 
A single-pass trans-membrane receptor, Kremen, was initially identified as a binding partner of a 
negative regulator of Wnt/β-catenin signaling, Dkk1. Upon binding to Dkk1, Kremen is internalized 
by endocytosis with LRP5/6, leading to a suppression of Wnt/β-catenin pathway [94]. 
 
Ror2 
The Ror family of receptor tyrosine kinases (RTK) consists of two structurally related proteins, 
Ror1 and Ror2. They have an extracellular CRD, a membrane proximal kringle (KR) domain, and 
intracellular cytoplasmic tyrosine kinase domain and a proline-rich domain near the c-terminus [95]. 
Ror2 has been shown to act as an alternative receptor or co-receptor for Wnt5a [96] [97]. In 
addition to its ability to bind Wnt5a, Oishi and colleagues reported the ability of Ror2 to bind some 
FZD receptors as well [97], suggesting that Ror2 might play a role as a co-receptor. The 
extracellular domain of Ror2 associates with Wnt5a but not with Wnt3a. Furthermore, Ror2 
mediates Wnt5a signaling by activating the Wnt/JNK pathway and/or inhibiting the β-catenin/Tcf 
pathday. It has also been shown that Ror2 interacts with filamin A and that it mediates 
Wnt5a-dependent cell migration [98].  
 
Strabismus / Van Gogh-like Protein 
Strabismus is a four-pass trans-membrane protein. There are two Strabismus genes in mouse and 
human. In human, they are known as human Strabismus-1 (also known as Van Gogh-like Protein-2) 
and human Strabismus-2 (also known as Van Gogh-like Protein-1). Although Strabismus does not 
bind with Wnt ligands, it can bind the PDZ domain of Dvl adopter proteins. This leads to the 
activation of JNK in PCP pathway and suppression of Wnt/β-catenin pathway [99]. 
 
Ryk 
Ryk is a single-pass transmembrane RTK and Ryk can interact at least with Wnt1 and Wnt3a [100]. 
Ryk family members have been shown to be required for Wnt signaling in several contexts. For 
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example, knockdown of Ryk reduces the Wnt1-dependent TCF activation in HEK-293 cells [100]. 
However, whether Ryk mediates Wnt signaling in concert with Fz-LRP5/6 or independently is not 
clear and also how Ryk activates the intracellular signaling cascade after binding to Wnt ligands has 
not yet been uncovered. 
 
2.2.3. Conservation of the WNT pathway 
Members of the WNT family of lipid-modified glycoproteins are found in most metazoans, ranging 
from the sea anemone Nematostella (starlet sea anemone) to humans [86] [101]. After the first 
finding of wingless in Drosophila, further studies revealed that the gene wingless is genetically 
related to other segmentation polarity genes, dishevelled (dsh), shaggy, armadillo, and pangolin. 
These genes were found to possess orthologs in mammalian. Namely, dishevelled is a homolog of 
mammalian gene Dvl, shaggy is GSK-3β, armadillo is β-catenin, and pangolin is TCF. These facts 
suggested that WNT signaling is well conserved during the evolution. 
 
On the other hand, from the embryologic point of view, in 1989, it was demonstrated that body axis 
of Xenopus early embryo (4-cell stage) is duplicated by the injection of mouse Wnt1 mRNA [102]. 
Together with the results from the genetic experiments in Drosophila, this observation supported 
the notion that WNT signaling is shared between vertebrates and invertebrates.  
 
A recent genome-wide study has revealed that mammalian species have roughly 20 secreted Wnt 
proteins, which can be divided into 12 conserved Wnt subfamilies (Fig.6). Of these, 6 subfamilies 
have counterparts in ecdysozoan animals such as Drosophila and Caenorhabditis. In contrast, at 
least 11 of the Wnt subfamilies occur in the genome of a cnidarian, the simplest metazoans with a 
nervous system, such as Nematostella (starlet sea anemone). While this suggests that some Wnt 
subfamilies were lost during the evolution of the ecdysozoan lineage, the most important thing 
suggested by these facts is that a complex Wnt factors had existed in multicellular animals well 
before the Cambrian explosion (550 million years ago) [86] [101].  
 
Being in line with these genetic, embryologic and genome-phylogenic findings, it has been revealed 
that WNT signaling plays important roles in many biological events in most metazoans. WNT 
signaling plays roles not only in embryonic development, but also in cell proliferation and 
differentiation in adult tissues. 
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Figure 6. Bayesian inference consensus tree of the Wnt gene family  
Bf=Branchiostoma floridae (amphioxus), Bm=Bombyx moori (insect), Ce=Caenohabditis elecans, 
Dm=Drosophila melanogaster, Hs, Homo sapiens, Hv=Hydra vulgaris, Nv=Nematostella vectensis 
(sea anemone), Pd=Plathynereis dumerlii (Polychaete), Pv=Patella vulgata (mollusc), 
Ag=Anopheles gambiae, Bilaterian genes are italicized, N. vectensis genes are in bold, the H. 
vulgaris gene is italic and bold. 
Kusserow et al. 2005 
 23
2.2.4. WNT pathways 
Upon binding of Wnt to its receptor, either Frizzled or a complex comprising Frizzled and LRP5/6, 
a signal is transduced to the cytoplasmic phosphoprotein Dishevelled (Dsh). There are three Dsh 
proteins in mammals (Dsh-1, Dsh-2 and Dsh-3). The ligand/receptor interaction has been shown to 
induce the phosphorylation of the Dsh family by casein kinase 1ε and -2 and PKCα. [103-105]. 
This event was reported to be a component of all Wnt-induced signaling pathways [106, 107]. At 
the level of Dsh, the Wnt signal branches into roughly three separate pathways, the canonical 
pathway (Wnt/β-catenin pathway), planer cell polarity (PCP) pathway and calcium pathway. Most 
importantly, the way in which Dsh couples and distributes Wnt signaling into the three signaling 
branches remains at best poorly understood. Furthermore, compared to the canonical pathway, PCP 
pathway and calcium pathway are largely unknown. Here, I will describe these three pathways. 
 
2.2.4.1. Canonical pathway (Wnt/β-catenin pathway) 
Historically called the “Canonical pathway” signaling is initiated when Wnt ligands engage their 
cognate receptor complex consisting of FZD family and a member of the LDL receptor family, 
LRP5/6. The central player is a cytoplasmic protein termed β-catenin, the stability of which is 
regulated by the destruction complex. When Wnt receptors are not engaged, two scaffolding 
proteins in the destruction complex, adenomatous polyposis coli (APC) and axin, bind newly 
synthesized β-catenin. CKI and GSK3, two kinases residing in the destruction complex, then 
sequentially phosphorylate a set of conserved Ser and Thr residues in the N-terminus of β-catenin. 
The resulting phosphorylated footprint recruits a β-TrCP-containing E3 ubiquitin ligase, which 
targets β-catenin for proteasomal degradation. In the presence of Wnt ligands, receptor occupancy 
inhibits the kinase activity of the destruction complex by an incompletely understood mechanism 
involving the direct interaction of axin with LRP5/6, and/or the actions of an axin-binding molecule, 
Dsh (Fig. 7) (Fig.8a). As a consequence, β-catenin accumulates, travels into the nucleus where it 
engages the N-terminus of DNA-binding proteins of the Tcf/Lef family [108] and initiates gene 
expression of target genes such as Cyclin D1 and c-Myc [109-111]. The vertebrate genome encodes 
four highly similar Tcf/Lef proteins. It is also reported that in the absence of a Wnt signal, certain 
Tcfs repress target genes through a direct association with co-repressors such as Groucho. The 
interaction with β-catenin transiently converts Tcf/Lef factors into transcriptional activataors. As a 
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consequence, the canonical pathway translates a Wnt signal into the transient transcription of a 
Tcf/Lef target gene program [112] [113],  
  
Figure 7. Model for the activation of the 
Wnt/β-catenin pathway 
 
(B) On binding of Wnt to the receptors, 
FZD and LRP, Dvl binds to FZD and 
recruits the destruction complex through 
interaction with axin. Subsequently, LRP is 
phosphorylated and acts as docking site for 
axin. (C) Binding of axin to LRP leads to 
inhibition of the destruction complex and 
stabilization of β-catenin. 
 
Fuerer, C and Nusse, R    2008 
 
2.2.4.2. Planar cell polarity (PCP) pathway and Ca2+ pathway 
In the PCP pathway Wnt signaling through FZD receptors mediates asymmetric cytoskeletal 
organisation and the polarization of cells by inducing modifications to the actin cytoskeleton. Two 
independent pathways, which are initiated by Dsh trigger the activation of the small GTPases Rho 
and Rac. Activation of Rho requires Daam-1 and leads in turn to the activation of the 
Rho-associated kinase ROCK. Rac activation is independent of Daam-1 and stimulates Jun Kinase 
(JNK) activity (Fig.8b) [114] [115]. In vertebrates, Strabismus is a four-TM molecule that recruits 
Dsh to a PDZ domain on its cytoplasmic tail [99]. Dsh interaction with Strabismus interferes with 
β-Catenin signaling and activates the PCP pathway. Evidence suggests that it is Wnt itself that 
determines the pathway involved. Canonical Wnts such as Wnt-1 and Wnt-3a block Strabismus 
binding of Dsh, and encourage its association with Frizzled. Wnt-5a and Wnt-11, however, promote 
Dsh interaction with Strabismus and block its association with Frizzled [116]. 
 
Wnt signaling via FZD receptors can also lead to the release of intracellular calcium. FZD 
co-receptors involved in this pathway include Knypek and Ror2. Other intracellular second 
messengers associated with this pathway include heterotrimeric G-proteins, phospholipase C (PLC) 
and protein kinase C (PKC). The exact genes activated by the Wnt/Ca2+ pathway are unknown, but 
NFAT, which is a transcription factor regulated by the calcium/calmodulin-dependent protein 
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phosphatase, calcineurin, appears to be involved. The Wnt/Ca2+ pathway is important for cell 
adhesion and cell movements during gastrulation (Fig.8c) [115, 117]. 
 
 
Figure 8. Three Wnt pathways branch at the level of Dsh  
(A) Canonical pathway requires DIX domain and PDZ domain of Dsh and leads to β-catenin 
stabilization. (B) In PCP pathway, activation of Rho requires Daam1 that binds to the PDZ domain 
of Dsh. Rac activation is independent of Daam1, but requires DEP domain of Dsh. (C) In calcium 
pathway, the signal via FZD mediates activation of heteromeric G proteins, which engage Dsh, PLC, 
CamK2 and PKC. This pathway also uses the PDZ and DEP domains of Dsh.    Habas et al. 2005 
 
2.2.5. WNT negative regulators 
2.2.5.1. sFRPs (Secreted Frizzled-related Proteins) 
First, I will describe sFRPs in general. Afterwards, I will also describe specifically sFRP1 in detail, 
since I examined the effect of sFRP1 on breast cancer during my PhD study. 
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The sFRPs are a group of Wnt-binding glycoproteins that resemble the transmembrane receptor 
FZD. Their actions are mainly considered to be inhibitory to Wnt activity, however, there are also 
some reports showing their actions stimulatory to Wnt activity at low concentrations [118].  
 
There are presently eight known members of the family, sFRP1 to sFRP5, Sizzled, Sizzled2 and 
Crescent. On the basis of sequence homology, sFRP1, sFRP2 and sFRP5 form a subgroup, as do 
sFRP3 and sFRP4, which are quite distantly related to the other sFRPs. Sizzled, Sizzled2 and 
Crescent form a third group, but they have not been identified in mammals and Drosophila [119] 
[120].  
 
All sFRPs are secreted and derived from unique genes and none are alternate splice forms of the 
FZD family [120]. They share sequence similarity with the Frizzled receptor CRD (cysteine rich 
domain), but lack the transmembrane and intracellular domains [121] [122] [123]. Through its CRD, 
sFRP exhibits the ability to bind Wnt. Furthermore, the CRD of sFRP1 also appears to interact with 
itself to make dimmers or multimers and with FZD [124]. Thus, sFRPs may block Wnt signaling 
either by interacting with Wnt proteins to prevent them from binding to FZD receptors or by 
forming nonfunctional complexes with FZD receptors [125] [126] [124]. 
 
sFRP1 
Human sFRP1 is also known as SARP2 (secreted apoptosis-related protein 2) and FrzA (Frizzled in 
aorta). In some human colorectal tumors, sFRP1 is found to be mutated. First, mutations in its gene 
create a stop codon at precursor position (3 out of 10 samples). Second, there can be a 1 aa insert at 
position 13, leading to the addition of an extra alanine residue (31% from colorectal cancer-free 
individuals and 35% from colorectal cancer patients). Additionally, there is an alternate splice form 
that removes the extreme seven C-terminal aa and replaces them with a new stretch of 30 aa. This 
new addition is suggested to serve as a membrane "anchor", creating a membrane-anchored receptor 
[127]. In addition to gene-directed changes, proteolytic processing creates multiple sFRP1 isoforms. 
In particular, the N-terminus is reported to begin at Ser4, Asp14, and Phe23 of the mature segment. 
The two shortest forms represent up to 17% of all sFRP1. Further, the C-terminal lysine is known to 
be selectively cleaved. The significance of this is unknown [128]. 
 
 27
sFRP1 has been reported to bind to Wnt1 [129] [124], Wnt2 [124, 130], Wnt8 [131], Wnt4 and 
Wnt3a [132] [133]. However, it does not bind to Wnt5a [129] [130]. In any event, in binding to 
Wnts, sFRP1 would seem to act primarily as an inhibitor of Wnt signaling [129] [118]. sFRP1 
binding to Wnt1 is reported to be antagonistic to Wnt activity [124]. sFRP1 also has been reported 
to protect cells from apoptosis, but this may be context dependent [134] [132] [135] [136]. Other 
functions associated with sFRP1 include endothelial cell migration and capillary tube formation 
[136], myofibroblast recruitment and collagen deposition, and a sFRP-induced decrease in MMP-9 
activity [134].  
 
2.2.5.2. WIF1 (Wnt-inhibitory fancor 1)  
WIF1 is a Wnt binding protein secreted by variety of tumors and embryonic tissues. WIF1 has an 
N-terminal signal sequence, a unique WIF domain (WD) that is highly conserved across species, 
and five EGF-like repeats. Although WIF1 does not share any sequence similarity with the CRD 
domain of FZD or sFRPs, it can bind to Wnt ligands [119]. It apparently does so by forming a 
non-covalent complex with Wnt8 and Wnt1 [137].  
   
2.2.5.3. Dkks (Dickkopfs) 
The Dkk family comprises four structurally-related members (Dkk1 to Dkk4) and a unique 
Dkk3-related protein named Soggy (Sgy), which possesses homology to Dkk3. Dkks contain two 
characteristic cysteine-rich domains separated by a linker region of variable length [138] [139]. 
Dkk1 is a negative regulator of Wnt-mediated LRP signaling. Dkk1 interacts with LRP5/6 and a 
single-pass transmembrane proteins Kremen1 (Krm1) and Kremen2 (Krm2), which are 
endocytosable molecules [94]. Using these interactions, Dkk1 can form a “bridge” between LRP 
and Kremen leading to the endocytosis of Kremen accompanied by internalization of Dkk/LRP. 
This internalization blocks LRP deactivation/destabilization of axin and results in the 
phosphorylation/degradation of β-catenin [119] [140] [141] (Fig.9). Thus, Dkk1 acts as a negative 
regulator of Wnt/β-catenin signaling, but not PCP signaling or calcium signaling.  
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Figure 9. Dkk1 inhibitory effect on 
Wnt/β-catenin signling 
 
Dkk1 interacts with LRP5/6 and the 
co-receptor Kremen1/2, and this triggers 
LRP5/6 endocytosis, thereby preventing 
formation of the LRP5/6-Wnt-FZD complex. 
As a result, b-catenin is degraded. 
   Kawano et al. 2003 
 
 
3. Role of WNT in cancer 
3.1. WNT signal abnormalities in human cancers 
A wide range of human cancers carry mutations in at least one component of the canonical 
Wnt/β-catenin pathway leading to a ligand-independent stabilization of β-catenin. One of the well 
known examples is colorectal cancer (CRC), in which approximately 85% of cases harbor 
loss-of-function mutations in the tumor suppressor gene, APC [142, 143]. Loss of APC function is 
seen at an early stage in colorectal carcinogenesis and is believed to be the initiating event for 
formation of adenomatous polyps [144]. Although APC is widely expressed in other tissues, the 
incidence of the mutations in APC is relatively rare [142, 143]. However, mutation in β-catenin is a 
more common event in other types of human cancers including colorectal, gastric, hepatocellular 
and ovarian cancers. Their incidence ranges from a few persent to as much as 80% [142, 143]. 
These mutations affect the N-terminal phosphorylation sites and thus render β-catenin resistant to 
phosphorylation and ubiquitination. Mutations in Axin is also found in 5-10% of hepatocellular 
carcinomas and in a small number of colorectal cancers lacking mutations in APC or β-catenin [142, 
143].  
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A principle that emerges from these studies is that potentially any mutations that results in elevated 
β-catenin levels without decreasing cell viability may contribute to a premalignant condition or 
tumorigenesis. Aberrant activation of the other PCP and calcium pathways in malignant tissue is 
less well characterized and their relevance to human cancer is largely unknown. 
 
3.2. WNT activation in breast cancer 
As described in former section, the discovery of Wnt1 as a mammary oncogene was brought from 
the study on mouse mammary tumor virus (MMTV) [145] [76]. MMTV acts as an insertional 
mutagen in mouse mammary tissue and in many MMTV-induced tumors, integration of proviral 
DNA results in transcriptional activation of the gene we know as Wnt1 [146].  
 
The immediate consequence of Wnt1 expression in the mouse mammary gland is hyperplasia rather 
than carcinoma. This is also evident from the phenotype of MMTV-Wnt1 transgenic mice, which 
show extensive lobulo-alveolar hyperplasia and subsequently develop focal mammary carcinomas 
after a long latency period [146, 147]. Despite this long latency, Wnt1 does have an oncogenic 
potential.  
In humans, there is no equivalent viral etiology demonstrated for breast cancer. Furthermore, 
although, N-terminal mutations of β-catenin have been detected in 45% (15 of 33) of breast 
fibromatosis cases, which are benign, stromal lesions [148](table 5), mutations in APC, Axin or 
β-catenin are rarely, if ever, detected in human breast carcinomas [149] [150] [151] [152]. However, 
there is documented overexpression of Wnts 1, 2, 3a, 4, 5A, 7B, 10B, 13 and 14 in human breast 
cancer tissues or cell lines (some of them are summarized on table 5) [153] [154, 155]. Furthermore, 
multiple FZD receptors are reported to be expressed in human breast cancer cell lines and primary 
tumors [156] [155]. Moreover, DVL1, a central regulator of WNT signaling, has been observed to 
be up-regulated in breast cancer (11 of 24 patients; 46% in mRNA level, 6 of 10 patients; 60% in 
protein level) [157]. Finally, around 60% of primary breast tumors show cytoplasmic or nuclear 
β-catenin localization rather than membrane localization [158] [159] [160] [161] and this was 
correlated with poor patient outcomes (Fig. 10) [160]. Taken together, these observations suggest 
that WNT signaling may frequently be de-regulated in breast cancer. 
However, the mechanisms by which breast cancer tissue shows aberrantly activated WNT signaling 
pathway have not yet been clearly understood. One possibility is an inactivation of genes coding 
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negative regulator of WNT signaling pathway. Since aberrant hypermethylation of gene promoters 
is a major mechanism associated with inactivation of tumor-suppressor genes in cancer [162], 
promoter hypermethylation of SFRP1 gene suggests one mechanism that might contribute to WNT 
pathway activity. In agreement with this hypothesis, promoter methylation of the gene coding 
sFRP1 is one of the most consistent observations in many cancers including breast cancer. There 
have been reports of the suppression of sFRP1 expression via promoter methylation in colon cancer 
[127, 163], ovarian cancer [164], bladder cancer [165] [166], mesothelioma [167], prostate cancer 
[168], lung cancer [169] and breast cancer [170].  
In primary breast tumors, expression of sFRP1 is reported to be lost in a high percentage, both at the 
RNA level (>75%) [171] [172] and at the protein level (>40%) [173]. Moreover, methylation of the 
promoter region of the SFRP1 gene was reported both in primary breast tumors (>60%) and breast 
cancer cell lines [170] [174] [175]. Interestingly, loss of sFRP1 protein expression and promoter 
hypermethylation is associated with disease progression and poor prognosis [173] [170]. Since 
aberrant hypermethylation of gene promoters is a major mechanism associated with inactivation of 
tumor-suppressor genes in cancer [162], promoter hypermethylation of SFRP1 gene suggests one 
mechanism that might contribute to WNT pathway activity.  
 
Table 5. Selected studies of WNT signaling pathway components in breast cancer and benign 
breast lesions 
Adapted from the review of Howe and Brown, 2004 
Signaling component Reported abnormality % cases Tumor type or samples 
sFRP1 loss/underexpression 80% carcinomas 
WIF1 reduced immunostaining 60% carcinomas 
Wnt2 overexpression, RNA 45% carcinomas 
Wnt2 overexpression, RNA 22% 1 degree breast cancers 
Wnt2, Wnt4 overexpression, RNA 80% fibroadenomas 
Wnt5a overexpression, RNA 36% carcinomas 
Wnt5a loss of immunostaining 36% carcinomas 
Wnt7b overexpression, RNA 10% carcinomas 
Wnt10b overexpression, RNA 6% carcinomas 
Wnt13/2b overexpression, RNA 14% carcinomas 
Wnt14 overexpression, RNA 11% 1 degree breast cancers 
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APC truncation mutation 4% Breast ca. cell lines 
APC truncation mutation 0.5% carcinomas 
APC truncation mutations 6% carcinomas 
APC reduced immunostaining 41% carcinomas 
APC truncation mutations 18% fibroadenomas 
β-catenin nuclear and/or cytoplasmic staining 60% 1 degree breast cancers 
β-catenin nuclear and/or cytoplasmic staining 63% 1 degree breast cancers 
β-catenin increased protein, but no mutation 13% carcinomas 
β-catenin nuclear staining, but no mutation 72% Phyllodes tumors 
β-catenin activating mutations 45% fibromatoses 
 
 
Figure 10.  
Aberrantly-localized β-catenin association with 
poor patient survival rate    Lin et al 2000 
 
 
 
II. AIMS OF THE WORK 
 
Currently, targeted therapeutics for breast cancer patients are endocrine treatment for ER+ breast 
tumors and trastuzumab treatment for ERBB2+ breast tumors. However, around 50% of breast 
cancer cases are neither ER+ nor ERBB2+. Furthermore, basal-like breast cancer, which shows the 
worst prognosis, accounts for 17-37% of breast cancer cases [70]. Thus, more targets are needed for 
breast cancer therapy.  
 
On the other hand, around 60% of primary breast tumors show cytoplasmic or nuclear β-catenin 
localization rather than membrane localization [158] [159] [160] [161] and this was correlated with 
poor patient outcome [160], suggesting that WNT signaling pathway is aberrantly activated in many 
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breast cancers. Since multiple WNT ligands are known to be expressed in breast cancer [153], one 
potential mechanism contributing to pathway activity might be loss of negative modulators of WNT 
signaling [176]; decreased expression of sFRP1 is well documented in human breast cancer [171] 
[173] [170] [174] [175].  
 
These reported evidences prompted us to hypothesize that activated WNT signaling pathway plays 
important roles in breast cancer formation and interference with WNT pathway by sFRP1 treatment 
might have effect on breast cancer cell proliferation and tumor growth. Based on these hypotheses, 
the main aims of my work have been, 1; to evaluate the importance of WNT pathway activation in 
breast cancer and 2; to evaluate whether sFRP1 treatment can block the breast cancer cell 
proliferation, tumor formation and tumor growth. 
 
 
III. RESULTS 
In the paper published by us in 2007 (Schlange et al. [177]), we showed a panel of breast cancer cell 
lines that have autocrine WNT signaling activity. Furthermore, interference with the activated 
autocrine loop using sFRP1 conditioned medium (CM) resulted in a decrease of active β-catenin 
and suppressed proliferation. In another project, we showed interference of autocrine WNT pathway 
by sFRP1 treatment affect cell migration and ectopic expression of sFRP1 suppresses in vivo tumor 
formation and tumor growth in xenograft model. 
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WNT signaling enhances breast cancer cell motility and blockade of the 
WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth 
 
Abstract 
Introduction 
In breast cancer deregulation of the WNT signaling pathway occurs by autocrine mechanisms. 
WNT ligands and Frizzled (FZD) receptors are coexpressed in primary breast tumors and breast 
cancer cell lines. Moreover, many breast tumors show hypermethylation of the promoter region of 
secreted Frizzled-related protein 1 (sFRP1), causing low expression of this WNT antagonist. We 
have previously shown that the WNT pathway influences proliferation of breast cancer cell lines via 
activation of canonical signaling and via EGFR transactivation. Furthermore, interference with 
WNT signaling in breast cancer cell lines reduces their proliferative ability. Here we examine the 
role of WNT signaling in breast tumor cell migration and on xenograft outgrowth.  
 
Methods 
Two sFRP1-negative human breast cancer cell lines, T47D and MDA-MB-231, were used to study 
WNT signaling. We examined the effects of activating or blocking the WNT pathway on tumor cell 
motility by treatment with WNT ligands or with sFPR1, respectively. Furthermore, the ability of 
MDA-MB-231 cells ectopically expressing sFRP1 to grow as xenografts in nude mice was tested. 
Finally, a microarray analysis was carried out in order to identify targets with roles in 
MDA-MB-231/sFRP1 tumor growth inhibition.   
 
Results 
We show here that WNT stimulates the migratory ability of T47D cells, while ectopic expression of 
sFRP1 in MDA-MB-231 cells blocks canonical WNT signaling and decreases the migratory potential 
of these cells. Moreover, outgrowth of MDA-MB-231/sFRP1 expressing cells as xenografts in nude 
mice is dramatically impaired compared to outgrowth of control tumors. A microarray analysis led to 
the identification of two genes, CCND1 and CDKN1A, whose expression level is selectively altered 
in vivo in sFRP1 expressing tumors. The encoded proteins, Cyclin D1 and p21Cip1 were down- and 
up-regulated, respectively, in sFRP1 expressing tumors, suggesting that they are downstream 
mediators of WNT signaling.    
 49
 Conclusions 
Our results show that the WNT pathway influences multiple biological properties of breast cancer 
cell lines. WNT stimulates tumor cell motility; conversely sFRP1 mediated WNT pathway blockade 
reduces motility. Moreover, ectopic sFRP1 expression in MDA-MB-231 cells has a strong negative 
impact on tumor outgrowth. These results suggest that interference with WNT signaling at the 
ligand-receptor level may be a valid therapeutic approach in breast cancer.   
 
Introduction 
The WNT signaling network is complex with 19 WNT ligands, 10 FZD receptors, as well as the 
co-receptors, low density lipoprotein receptor-related protein 5 (LRP5) and LRP6. WNT receptor 
binding stimulates intracellular signaling promoting stabilization and nuclear translocation of the 
key effector of the canonical pathway, β-catenin [101] [178]. In many human cancers, intracellular 
mediators of the WNT pathway are mutated. Inactivating mutations in the APC or the AXIN genes, 
as well as activating CTNNB1 (encoding β-catenin) mutations all cause β-catenin stabilization and 
nuclear accumulation in the absence of WNT ligands. In the nucleus, β-catenin forms functional 
complexes with transcription factors of the LEF-1/T-cell factor (TCF) family, activating expression 
of target genes with cancer promoting roles [153]. In addition to activation of the canonical pathway 
by engagement of FZD and LRP receptors, WNT ligands bind the Ror2 or Ryk receptors to 
stimulate β-catenin independent pathways that have been involved with cytoskeletal reorganization 
and cell migration [178] [179]. 
 
In breast cancer, deregulation of WNT signaling appears to occur by autocrine mechanisms [180] 
[181] [177]. Multiple WNT ligands and FZD receptors are expressed in primary human breast 
tumors and in breast cancer cell lines [153, 177] [154, 156]. Furthermore, most breast tumors show 
hypermethylation of the promoter region of sFRP1 and low expression of this negative WNT 
pathway regulator [170, 171, 173].  
 
WNT signaling influences biological processes ranging from cell fate to cell motility, proliferation 
and apoptosis. We have previously shown that interference with autocrine WNT signaling blocks in 
vitro proliferation of many human breast cancer cell lines [177]. We have extended these studies 
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and show here that blocking the WNT pathway in T47D and MDA-MB-231 breast cancer cells not 
only decreases proliferation, but also impairs motility of the tumor cells. Furthermore, stable 
expression of sFRP1 in MDA-MD-231 cells has a dramatic effect on the ability of the cells to grow 
as tumor xenografts in nude mice. A microarray analysis led to the identification of two genes, 
CCND1 and CDKN1A, whose expression level is selectively altered in vivo in sFRP1 expressing 
tumors. The encoded proteins, Cyclin D1 and p21Cip1 were down- and up-regulated, respectively, in 
sFRP1 expressing tumors, suggesting that they are downstream mediators of WNT signaling 
involved in growth inhibition. These results provide further evidence supporting approaches to 
target WNT pathway activity in breast cancer.    
   
Results 
Wnt1 stimulates migration of T47D breast cancer cells 
The WNT signaling network controls many biological processes through canonical and 
noncanonical signaling, via β-catenin stabilization and RhoA activation, respectively. We have 
previously shown that autocrine WNT signaling stimulates proliferation of breast cancer cell lines 
via the canonical signaling pathway [177]. In the following experiments we explored the role of 
WNT signaling in breast tumor cell migration in a wound healing assay. Confluent monolayers of 
T47D breast tumor cells were scratched and the medium was changed to Wnt1 conditioned medium 
(CM) or control CM. Cultures treated 3 hours with Wnt1 CM showed elongated cells at the wound 
edges (Fig 1A, top panel). An analysis of closure kinetics of the wounded area, which was 
monitored 3 and 7 hr later, revealed that Wnt1 treated cultures closed the wound significantly more 
rapidly than cultures treated with control medium (Fig 1A lower panel). The effect was Wnt1 
specific since addition of the WNT antagonist sFRP1 to the Wnt1 CM reversed its effects so that the 
time for recovery of the wounded area was the same as measured in control cells (Fig 1A lower 
panel).     
 
Wnt1 was also stably expressed in the T47D breast cancer cells. We have previously shown that 
ectopic Wnt1 expression in these cells stimulates canonical signaling and induces an increase in 
level of active β-catenin [177]. We examined the migratory ability of the Wnt1 expressing T47D 
cells in a clone with high Wnt1 levels (clone 1), and in a pool of T47D cells with lower levels of 
Wnt1 (P1) (Fig 1B). Confluent cultures of T47D/Wnt1-clone1 and T47D/Wnt1-P1 as well as 
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control cultures were scratched and recovery of the wounded area was monitored 3 hr later. In 
comparison to the control cultures, both the clone and the pool of Wnt1 expressing cells migrated 
significantly more rapidly (Fig 1C). These results suggest that activation of WNT signaling 
promotes motility of T47D breast cancer cells.  
 
Elevated RhoA activity in T47D/Wnt1 cells 
Remodeling of the actin cytoskeleton is a crucial step in cell migration [182]. Indeed, T47D cultures 
treated with Wnt1 CM have more prominent actin stress fibers compared to control cultures (Fig 
2A). Prompted by this morphological change and the known ability of some WNTs to stimulate 
RhoA [183, 184], RhoA activity was measured in lysates made from control T47D cultures and 
from T47D/Wnt1-P1 cultures. The active GTP-bound form of RhoA was captured in a pull-down 
assay with the GST-C21 fusion protein and examined by a western analysis for RhoA levels using a 
RhoA specific antiserum. Both cell lines have similar overall RhoA levels, however the Wnt1 
expressing cells have 3.9-fold more active, GTP-bound RhoA compared to control cells (Fig 2B). 
These results suggest that one of the mediators of Wnt1 stimulated tumor cell migration is RhoA.  
 
Ectopic sFRP1 expression in MDA-MB-231 cells blocks WNT signaling 
In breast cancer, low levels of sFRP1 combined with co-expression of WNT ligands and FZD 
receptors contribute to WNT pathway activation [154, 177]. MDA-MB-231 cells, a model of basal 
breast cancer [72], do not express sFRP1 mRNA as determined by a qRT-PCR analysis (data not 
shown). Furthermore, active, stabilized β-catenin is present in MDA-MB-231 cells [177], 
suggesting that WNT signaling is constitutively activated. We examined the effects of blocking 
WNT pathway by restoring sFRP1 expression in the MDA-MB-231 breast tumor cells. Vectors 
encoding Myc-tagged sFRP1 and the empty control were transfected into MDA-MB-231 cells and 
stable clones were selected in G418-containing medium. Three MDA-MB-231/sFRP1 clones 
expressing moderate to strong levels of the Myc-tagged sFRP1, as well as control clones were 
selected for further analyses (Fig 3A).   
 
WNT pathway activity was examined in the cells using various markers. As a consequence of WNT 
binding to FZD, cytoplasmic scaffolding proteins of the Dishevelled family (DVL1, -2 and -3) 
become phosphorylated on serine and threonine residues. DVL phosphorylation, which is the most 
proximal signaling event downstream of WNT-mediated FZD activation, can be monitored by a 
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decrease in the electrophoretic mobility of p-DVL [106, 185]. DVL1, -2 and -3 and stabilized, 
unphosphorylated active β-catenin, were examined in a western analysis in the individual clones. 
Each of the 3 DVLs showed an enhancement in the lower non-phosphorylated form in the sFRP1 
expressing cells, compared to the vector control cells. Furthermore, a band of active β-catenin is 
readily detectable in the control cells, while in the two clones expressing the highest level of sFRP1 
there was a strong decrease in active β-catenin levels (Fig 3A). The activity of other signaling 
pathways was also examined in the sFRP1 expressing MDA-MB-231 cells.  These cells display 
high levels of phosphorylated ERK1/2, very likely due to the fact that they possess an activating 
K-Ras mutation [186]. sFRP1 mediated inhibition of the WNT pathway did not alter phosphorylated 
ERK1/2 levels (Fig3A).  
 
For further studies, the three sFRP1 expressing clones were pooled (P1), and a second pool of 
sFRP1-expressing MDA-MB-231 cells, consisting of >100 clones was generated (P2). A 
quantification of the western analysis carried out on both pools shows that P1 has 2.8-fold higher 
levels of sFRP1 than does P2 (Fig 3B). The lower level of sFRP1 in P2 is likely due to the fact that 
these cells was prepared from retrovirally infected MDA-MB-231 cultures, while the P1 clones 
originated from a transfection. 
 
We have previously shown that treatment of various human breast cancer cell lines with purified 
sFRP1 or with sFRP1 CM lowers their proliferative ability[177]; proliferation of MDA-MB-231 
cells were also inhibited by treatment with sFRP1 CM (Supp Fig 1). Furthermore, ectopic 
expression of sFRP1 in MDA-MB-231 cells also decreases the proliferative ability of the cells in 
comparison to control cells (Fig 3C). This effect appears to be dependent on sFRP1 expression 
levels since, in comparison to controls, there is a 31% and a 16% reduction in proliferation of 
MDA-MB-231/sFRP1-P1 and -P2 cells, respectively (Fig 3C). 
 
We also examined the ability of MDA-MB-231/sFRP1-P1 cultures and control P1 cultures to 
migrate in a wound healing assay. In response to Wnt1 CM, the control MDA-MB-231 cells 
migrated significantly more rapidly into the wounded area compared to cultures treated with control 
CM (Fig 3D gray bars). These results are similar to what was observed for the T47D cultures 
treated with Wnt1 CM (Fig 1A). In contrast, Wnt1 treatment of MDA-MB-231/sFRP1-P1 cells did 
not significantly stimulate migration, reflecting the ability of sFRP1 to block Wnt1 mediated FZD 
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activation (Fig 3D black bars). In summary, ectopic expression of sFRP1 in MDA-MB-231 cells 
down-regulates WNT pathway activity, leading to a decrease in proliferation and in the ability of 
Wnt1 to stimulate migration.  
 
Xenografts of sFRP1 expressing MDA-MB-231 cells show reduced growth in nude 
mice 
To test the in vivo effects of sFRP1, control and sFRP1 expressing MDA-MB-231 cells (P1 and P2) 
were injected into the mammary fat pads of female nude mice and tumor growth was monitored (Fig 
4 and Supp Fig 2). There was a significant reduction in tumor outgrowth in mice injected with 
MDA-MB-231/sFRP1-P1 cells (p<0.01, Two-way RM ANOVA) (Fig 4A left panel). Furthermore, 
the time to detection of the first tumors was significantly shorter following injection of control 
MDA-MB-231 cells, compared to MDA-MB-231/sFRP1-P1 cells (23 days vs 35 days, respectively) 
(Fig 4A right panel). Moreover, in this experiment, 3 mice injected with the 
MDA-MB-231/sFRP1-P1 cells remained tumor-free at day 45, when the experiment was terminated. 
In contrast, all of the mice injected with control MDA-MB-231 cells had tumors (Fig 4A, right panel). 
MDA-MB-231/sFRP1-P1 cells were tested in three additional independent experiments (Supp Fig 2 
and data not shown). While there was some variation in the time of tumor onset in the independent 
experiments, the time to appearance of the first tumor was consistently longer following injection of 
the MDA-MB-231/sFRP1 cells, in comparison to control cells. Furthermore, MDA-MB-231/sFRP1 
tumors grew more slowly than control tumors, and the number of tumor-free mice at the end of each 
experiment was always higher (Supp Fig 2).  
 
Interestingly, MDA-MB-231/sFRP1-P2 cells that express almost 3-fold less sFRP1 compared to P1 
cells (Fig 3B) also grew more slowly than control cells. Although the effect on tumor growth did not 
reach significance using Two-way RM ANOVA (Fig 4B left panel), tumor onset was delayed 
significantly in the cohort injected with MDA-MB-231/sFRP1-P2 cells (p=0.026, log-rank test) (Fig 
4B right panel). Furthermore, all of the mice had tumors at the end of the experiment (Fig 4B, right 
panel). The in vivo results together with the data on in vitro proliferation (Fig 3C) suggest that higher 
levels of sFRP1 lead to a stronger blockade of WNT pathway activity and to a stronger effect on 
proliferation and tumor onset.  
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Mechanisms contributing to the in vivo anti-tumor effects of sFRP1  
Our next goal was to reveal the mechanism underlying the ability of sFRP1 to decrease the mammary 
tumor-forming potential of MDA-MB-231 cells. Initially we tested the tumors for continued sFRP1 
expression. A western analysis carried out on lysates from tumors arising from 
MDA-MB-231/sFRP1-P1 cells revealed that sFRP1 levels remained high. Furthermore, WNT 
signaling was strongly down-regulated, as shown by a decrease in the P-DVL3 levels in the sFRP1 
expressing tumors compared to control tumors (Fig 4A left panel, insert). These results suggest that 
the slow outgrowth of sFRP1 expressing MDA-MB-231 xenografts does not reflect a selection for 
tumor cells that down-regulated sFRP1 expression.  
 
The mechanisms underlying the ability of sFRP1 to impair tumor growth might be tumor cell 
intrinsic, resulting from down-regulation of WNT signaling, and/or extrinsic via effects of secreted 
sFRP1 on tumor-associated cells. We tested both possibilities in the following experiments. In vivo 
tumor cell proliferation was evaluated by examining bromodeoxyuridine (BrdU) incorporation in 
control and sFRP1 expressing tumors. Incorporated BrdU was detected with a specific antiserum (Fig 
5A left panel) and staining was quantified. There was a 70% reduction in BrdU staining in tumors 
arising from MDA-MB-231/sFRP1-P1 cells compared to control tumors (Fig 5A right panel). 
Apoptosis, as measured by western blotting for cleaved caspase-3, was low in the MDA-MB-231 
control tumor lysates and was not increased in the MDA-MB-231/sFRP1-P1 tumor lysates (data not 
shown). These results suggest that sFRP1 downregulation of WNT signaling has a strong effect on 
tumor cell proliferation, but not survival.  
 
sFRP1 has been reported to block in vivo neovascularization [187]. Thus, we considered the 
possibility that the density or the functionality of the tumor-associated vessels might be impaired in 
sFRP1 expressing tumors. Vasculature was visualized by FITC-labeled L. esculentum lectin [188], 
which was injected in the tail vein of tumor-bearing mice 5 min before the animals were sacrificed. 
Only functional vessels will be perfused with lectin in this experiment. Tumor sections were prepared 
and the associated endothelial cells were stained for CD31, while functional vessels were visualized 
via the FITC signal. There was no significant difference in the total vessel area or the ratio of FITC 
positive/CD31 positive vessels in sFRP1 expressing tumors compared to control tumors (Fig 5B left 
panel and right panels, respectively). Thus sFRP1 expressed by the tumor cells does not appear to 
influence the number or the functionality of tumor-associated blood vessels. In summary, these 
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results suggest that sFRP1 mediated blockade of WNT pathway activity in tumor cells is the most 
important factor contributing to the slower outgrowth of the MDA-MB-231/sFRP1 tumors in 
mammary glands.   
 
Analysis of c-Myc in the MDA-MB-231/sFRP1 tumor model 
Based on our previous results showing that siRNA mediated knock-down of c-Myc in MDA-MB-231 
cells lowers their in vitro proliferation [189] and the fact that c-Myc is a target gene of the WNT 
pathway in colon cancer models [190], we examined c-Myc in MDA-MB-231/sFRP1 cultured cells 
and derived tumors. qRT-PCR analyses revealed that there was no significant difference in c-Myc 
RNA levels in MDA-MB-231/sFRP1 tumor cells or cultured cells in comparison to control tumor 
cells or control cultured cells (Fig 6A). Interestingly, western analyses carried out on tumor lysates 
revealed a strong decrease in c-Myc protein levels in MDA-MB-231/sFRP1-P1 tumors compared to 
control tumors (Fig 6B left panel); while the level of c-Myc was not altered in the cultured 
MDA-MB-231/sFRP1-P1 cells compared to control cells (Fig 6B right panel).  
 
These results suggest that in the MDA-MB-231 cells, c-Myc is not a WNT target gene. Moreover, 
c-Myc protein appears to be subjected to different control mechanisms in the tumor environment 
compared to in vitro cultured cells. Nevertheless, we considered it possible that the lower level of 
c-Myc might be at least partially responsible for the slower tumor outgrowth kinetics of the 
MDA-MB-231/sFRP1 cells. Thus, we tested whether ectopic c-Myc expression might alter the 
growth-suppressed phenotype of MDA-MB-231/sFRP1 tumors. Accordingly, 
MDA-MB-231/sFRP1-P1 cells were infected with a c-Myc-encoding retroviral vector or a control 
vector and following selection in antibiotic-containing medium, pools of clones were generated. 
c-Myc infected MDA-MB-231/sFRP1 cells have elevated c-Myc levels compared to cells infected 
with the control vector (Supp Fig 3A). In vitro proliferation was monitored 3 and 4 days after seeding, 
revealing a slight, but non-significant increase in cell number in the MDA-MB-231/sFRP1/Myc cells 
compared to the MDA-MB-231/sFRP1/control cells (Supp Fig 3B). In the final experiment we tested 
the in vivo tumor forming ability of the cell lines. MDA-MB-231/sFRP1/Myc cells and 
MDA-MB-231/sFRP1/control cells were injected into fat pads of nude mice and tumor outgrowth 
kinetics was monitored. Forty-one days later, 2/6 mice injected with MDA-MB-231/sFRP1/Myc cells 
had tumors whereas none of the MDA-MB-231/sFRP1/control cells gave rise to tumors (Supp Fig 
3C). Although we observed a tendency that ectopic c-Myc expression rescues the growth potential in 
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vitro and tumor forming potential in vivo of MDA-MB-231/sFRP1 cells, the results did not reach 
significance, suggesting that additional targets might have roles in the growth suppression phenotype.  
 
Identification of genes whose expression level is selectively altered in vivo in sFRP1 
expressing tumors   
In order to identify WNT pathway targets that are controlled by sFRP1 expression and influence 
proliferation of the MDA-MB-231 cells, we undertook a genome-wide transcriptome analysis using 
microarrays. RNA isolated from individual tumors arising after injection of 
MDA-MB-231/sFRP1-P1 cells and MDA-MB-231/control-P1 cells, as well as RNA from in vitro 
cultured MDA-MB-231/sFRP1-P1 cells and MDA-MB-231/control-P1 cells was analyzed.  
 
Considering data generated from the tumors (6 sFRP1 tumors and 5 control tumors), there were 1753 
probesets (1246 genes) whose signals were changed more than 1.5 fold (p-value < 0.01 using a 1-way 
ANOVA) in the tumors arising from MDA-MB-231/sFRP1-P1 cells compared to tumors arising 
from MDA-MB-231/control-P1 cells. The same analysis performed on in vitro cultured samples 
revealed 428 probesets (332 genes) that had a 1.5 fold difference (p-value < 0.01 using a 1-way 
ANOVA). Only 69 probesets (54 genes) overlapped between the two analyses showing that gene 
expression profiles generated from in vivo tumors differ substantially from those of in vitro cultured 
cells. A functional analysis using the Ingenuity’s Pathway Analysis suite was also performed on the 
1753 probesets, in order to identify the biological functions and diseases that were significantly 
represented in the in vivo data set (Supp Fig 4). This analysis revealed a significant enrichment in the 
group of genes categorized as “cancer” (Fisher’s probability p=2.48E-12 to 1.41E-02) (Supp Fig 4A). 
Within this group, the most significant sub-group (266 genes) is “tumorigenesis” (Supp Fig 4B) 
(Fisher’s probability, p=2.48E-12).  
 
Cell cycle regulators are altered in sFPR1 expressing MDA-MB-231 xenografts  
In vitro proliferation of MDA-MB-231/sFRP1-P1 cells was decreased by 30% compared to control 
cultures (Fig 3C). In comparison, the in vivo effects of WNT pathway blockade appeared to be 
stronger, e.g, outgrowth of MDA-MB-231/sFRP1-P1 tumors was significantly slower and in each 
experiment tumor-free mice remained in this cohort. Thus, we also screened the 1753 probesets for 
genes whose expression was significantly altered only in tumors arising from 
MDA-MB-231/sFRP1-P1 cells compared to: tumors arising from MDA-MB-231/control-P1 cells, 
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cultured MDA-MB-231/sFRP1-P1 cells or cultured MDA-MB-231/control-P1 cells. Using the 
“Profile Distance Search” function of Gendata’s Analyst 4.5 tool, probes were sorted out of the 1753 
probesets. This resulted in 135 probesets (106 genes) that were down-regulated (Fig 7A) and 84 
probesets (62 genes) that were up-regulated (Fig 7B), in tumors arising from 
MDA-MB-231/sFRP1-P1 cells (Supp Table 1 lists the genes and their fold change). Two of the 
identified genes, CCND1 and CDKN1A were further analyzed based on their known roles in cell 
cycle regulation and proliferation.  
 
The microarray analysis showed that the signal from one probeset for CCND1 was down-regulated 
and the probeset for CDKN1A was up-regulated in vivo in tumors resulting from 
MDA-MB-231/sFRP1-P1 cell injection (Fig 7C). Next, we examined protein expression for each. 
Cyclin D1 was examined by immunohistochemistry (IHC) in tumor sections using a specific 
antiserum. Quantification of the staining showed a 30% decrease in Cyclin D1 levels in the sFRP1 
expressing tumors compared to control tumors (Fig 8A), results that agree well with the microarray 
analysis (Fig 7C). A western analysis for Cyclin D1, carried out on lysates prepared from 
MDA-MB-231/sFRP1-P1 cultures and control cultures, revealed no significant difference in 
expression between the two cell lines (Fig 8B). Next, p21Cip1 protein levels were measured by western 
analysis on lysates from MDA-MB-231/sFRP1-P1 tumors and control tumors, as well as lysates from 
the corresponding in vitro cultured cells. p21Cip1 was readily detected in tumors resulting from 
injection of MDA-MB-231/sFRP1-P1 cells. A representative tumor is shown in Fig 8C and 
quantification revealed a 3-fold increase in p21Cip1 levels in the sFRP1 expressing tumors compared 
to control tumors (Fig 8D). Neither of the in vitro cultured cell lines (MDA-MB-231/sFRP1-P1 or 
MDA-MB-231/control-P1) had detectable levels of p21Cip1 (Fig 8C). For this experiment, the p21Cip1 
positive MCF7 cell line (+CTRL) and a siRNA mediated p21Cip1 KD MCF7 cell line (-CTRL) served 
as antibody controls (Fig 8C). Thus p21Cip1 protein levels also reflect data generated from the 
microarray analyses. In summary, the in silico analysis of tumors arising from the 
MDA-MB-231/sFRP1 cells revealed target genes that very likely contribute to the strong 
anti-proliferative effects of sFRP1 expression. Moreover, this analysis also shows the strong 
influence of the in vivo tumor environment on gene expression. 
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Supplemental experiments 
sFRP1 expression and promoter methylation status of sFRP1 genes in breast cancer 
cell lines 
sFRP1 is a WNT antagonist which can compete with Frizzled receptors in binding to WNT ligands 
[123, 125, 129, 130, 191, 192]. Many primary breast tumors have little or no sFRP1 expression, 
likely due to promoter hypermethylation [170] [173] [193]. To study sFRP1 in breast cancer, we 
examined mRNA levels and promoter methylation of SFRP1 genes in seven human breast cancer 
cell lines. 
 
sFRP1 RNA expression was examined in a panel of breast cancer cell lines and a normal breast cell 
line using qRT-PCR. sFRP1 RNA was expressed in the normal breast cell line, MCF10A and HER2 
over-expressing breast cancer cell lines, JIMT1 and BT20, basal type breast cancer cell lines, 
HCC1937, BT549 and MDA-MB-468. On the other hand, sFRP1 RNA was not detected in the ER+ 
breast cancer cell lines, T47D and MCF7, HER2 over-expressing breast cancer cell lines, SkBr3 and 
BT474, basal type breast cancer cell line, MDA-MB-231 (Fig 9A), suggesting that sFRP1 
expression status is independent of ER+ and HER2 over-expression status. Next we examined the 
methylation status of SFRP1 gene promoter region. The promoter region of SFRP1 gene was 
methylated in MDA-MB-231 and BT474, half-methylated in T47D. These three cell lines were all 
sFRP1 RNA negative. On the other hand, the sFRP1 positive cell lines, MDA-MB-468, HCC1937, 
BT549, BT20 and MCF10A had unmethylated sFRP1 promoter region (Fig 9B). These results 
suggest that the suppression of sFRP1 expression in breast cancer cell lines mostly results from the 
promoter hypermethylation of SFRP1 gene.   
  
Ectopic expression of sFRP1 has effects on cancer stem cell phenotype. 
Recently, studies of neoplastic tissues have provided evidence of self-renewing, stem-like cells 
within tumors, which have been called cancer stem cells (CSCs). In most of the cases CSCs 
constitute a small minority of neoplastic cells within a tumor and are defined operationally by their 
ability to seed new tumors [194]. To date, studies using several immortalized cancer cell lines, 
including the human breast cancer cell line MCF-7, have indicated that they contain a 
subpopulation of highly tumorigenic cells which retain stem/progenitor-like properties [195-197]. 
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On the other hand, studies in choronic myelogenous leukemia indicate that the elevated levels of 
nuclear β-catenin exist in a minor population of progenitor cells, resulting in their enhanced 
capacity for self-renewal and increased leukemic potential [198]. Further evidence of dysregulation 
of stem/progenitor cell self-renewal and maintenance by the WNT/ β-catenin pathway have been 
demonstrated in lung cancer, colorectal cancer and gastrointestinal cancer [113, 199-202]. 
 
In the breast, a resent report showed that overexpression of β-catenin increased the 
mammosphere-forming efficiency and depleting endogenous β-catenin by using the dominant 
negative molecule of β-catenin decreased mammosphere forming efficiency [203]. Since 
mammosphere assay is an assay for self-renewal based on the hypotheses that stem cells may 
survive in anchorage-independent conditions whereas differentiated cells need attachment to 
survive and die by anoikis when they lose contact with extracellular matrix, the report from Chen et 
al suggests that β-catenin is required in the self-renewal process. 
 
Together with our result showing that tumor xenograft formation is dramatically suppressed by the 
ectopic expression of sFRP1 in MDA-MB-231 cells, these reported observations prompted us to 
check whether the ectopic expression of sFRP1 reduces CSC population. For this, we first checked 
the cell surface protein, CD44 and CD24. 
 
CD44 and CD24 are two cell-surface markers whose expression in the CD44high/CD24low 
configuration is associated with both human breast CSCs and normal mammary epithelial stem cells 
[204, 205]. In fact, a subpopulation from human mammary epithelial cells (HMLEs) showing the 
CD44high/CD24low antigenic phenotype have increased ability to form mammospheres in comparison 
to the subpopulation showing CD44low/CD24high antigenic phenotype [206]. Since mammospheres 
are enriched in stem cells and can seed entire mammary epithelial trees when implanted into cleared 
mammary fat pads [207-209], CD44high/CD24low antigenic phenotype appears to be a reliable marker 
of breast CSCs. Furthermore, CD44 has been reported to be a target gene of WNT/β-catenin 
pathway [210].  
 
Microarray analysis on MDA-MB-231 cells showed that CD44 levels were decreased and CD24 
levels were increased upon the ectopic expression of sFRP1 both in vitro cultured P1 cells and in 
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vivo P1 tumor lysates (Fig 10A). We confirmed the result in cultured cells by FACS analysis to see 
the cell surface protein level of CD44/24. FACS analysis showed CD44high/CD24low antigenic 
phenotype was suppressed upon sFRP1 expression in P1 cultured cells (Fig 10B). 
 
The report showing that the CD44high/CD24low antigenic phenotype is enriched in basal-like breast 
tumors [211] prompted us to check the expression levels of basal cytokeratins, 5/14 and 17. 
Interestingly, the expression of KRT14 and KRT17 were suppressed upon sFRP1 expression 
specifically in vivo, while the expression level of KRT5 was too low for further analyses. On the 
other hand, the expression of luminal cytokeratines, KRT8 and KRT18 were increased upon ectopic 
sFRP1 expression both in vitro and in vivo (Supp Fig 6).  
 
We also used CD29 (β1-integrin) as an indicator of tumor stem cells. CD29 is a stem-cell marker in 
the skin [212]. Furthermore, cells expressing high level of CD29 are reported to have a mammary 
stem cell potential and the population of CD29high cells is expanded in the mammary tissue from 
MMTV-WNT-1 mice [213]. 
 
Microarray analysis showed that CD29 mRNA level was suppressed upon the ectopic expression of 
sFRP1 both in vitro cultured P1 cells and in vivo P1 tumor lysates (Fig 11A). We confirmed the in 
vitro result by FACS analysis to see the cell surface protein level of CD29. FACS analysis using P1 
pools also showed number of CD29 positive cells decreased to 87% upon the ectopic expression of 
sFRP1 (Fig 11B).  
 
SOX2 is a marker of embryonic stem cells [214, 215]. It is not merely a synergistic factor in the 
regulatory network to maintain stemness, but a factor whose requirement alone is needed to 
preserve self-renewal and pluripotency in human ES cells. It has been recently shown that SOX2 
regulates self-renewal and pluripotency in human ES cells [216]. 
 
Canonical WNT signaling was shown to be an upstream regulator of SOX2 expression during 
vertebrate development and potentially in embryonic stem cells [217] [218]. There are potential 
TCF/LEF-binding sites in some of the multiple SOX2 enhancer regions that are conserved between 
vertebrate species, suggesting that SOX2 is a direct target for Wnt/β-catenin signaling [219, 220]. 
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In addition, SOX2 was recently shown to be expressed in a subset of basal-like breast cancers in a 
scattered fashion that suggests that it may demarcate a stem-like population [221]. The PCR 
analysis using the MDA-MB-231/sFRP1 clones and a control clone showed that SOX2 expression 
was low in MDA-MB-231 cells and down-regulated by sFRP1 (Fig 10C). This result suggests that 
the blockade of WNT pathway by sFRP1 expression suppress the SOX2 expression, leading to 
suppression of tumor stem cell phenotype. 
 
Increasing evidence suggests that stem/progenitor cells evade cell death by a number of 
mechanisms, such as quiescence and drug-efflux conferred by the ABC-family of membrane 
transporters [222]. A ´side population` was defined based on the efflux capability of a 
subpopulation of tumor cells for Hoechst dye. This efflux activity requires ATP-dependant 
transporters and can be blocked by specific inhibitors such as reserpine [223], which was shown 
previously to be an inhibitor of the Bmr efflux pump of Bacillus subtilis[224]. Tumor initiating cells 
were shown to possess an elevated activity of drug efflux transporters that may be responsible for 
their increased resistance towards chemotherapeutics [222, 225]. 
 
Therefore, we asked whether this additional property of tumor initiating cells is affected by 
inhibition of autocrine WNT signaling by the treatment of sFRP1 CM. The side population of 
MDA-MB-231 cells is reduced more than 6-fold from 0.77% in control CM treated cells vs. 0.12% 
in sFRP1 CM treated cells after 7d (Fig 10D). Furthermore, the expression of ABCA2, a member of 
the ABC super family whose expression has been correlated with drug resistance [226] [227] [228], 
was suppressed upon sFRP1 expression both in vitro and in vivo (Fig 10E). This implies that WNT 
signaling controls the ability of tumor initiating cells to efflux Hoechst dye and may therfore be 
involved in the development of drug resistance by regulating ATP dependant drug transporters. 
 
Taken together, these findings suggest that autocrine WNT signaling regulates some of the 
characteristics of tumor initiating cells by 1) regulating extracellular matrix molecule expression 
that may be required to form a tumor ´stem cell niche`, 2) regulating the expression of 
differentiation/stemness factors that maintain a multipotent state of the tumor initiating cells and 3) 
by controlling the drug efflux capability of tumor initiating cells and thereby a possible mechanism 
of multi-drug resistance." 
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P-cadherin level was up-regulated by WNT signaling in T47D cells 
Cadherins were first classified as a family of single-pass transmembrane glycoproteins mediating 
Ca2+-dependent cell–cell adhesion [229]. Members of Cadherin superfamily are classified into four 
groups: classical cadherins, desmosomal cadherins, protocadherins and other cadherin-related 
proteins [230]. Among them, the classical cadherins are present throughout metazoan [231].    
  
Classical cadherins have the signal sequence at the N-terminal site which is flanked by a 
prosequence that contains a protease processing signal sequence. The proteolytic cleavage at this 
site appears to be necessary for the activation of the classical cadherins. The extracellular domain is 
located next to this prosequence followed by single transmembrane segment and the cytoplasmic 
domain, which is located at the C-terminal side. The cadherin extracellular domain consists of five 
repeats of a cadherin motif, C1-5, where C1 is the most distant from the membrane and harbors an 
HAV (histidine-alanine-valine) tripeptide. Each of C1-C5 motif have Ca2+-binding site.  
 
In the absence of Ca2+, the cadherin structure is disorganized and incapable of participating in 
adhesion. As Ca2+ concentrations are increased, the C1-C5 subdomains start to bind Ca2+ ions and 
these subdomains become organized (C1, which has the lowest affinity for calcium, becomes 
organized last) and the cadhein ectodomain becomes rigid and competent to participate in 
cis-dimerization. When C1 becomes organized at higher calcium concentrations, steric 
rearrangements shift Trp (W) at the amino acid residue 2 to duck into the intramolecular 
hydrophobic pocket formed in part by the high conserved HAV sequence. The HAV-W structure is 
essential for trans-dimerization but not cis-dimerization [232] (Figure below). 
 
In the cytoplasmic domain, at least two functional sequences have been identified: a well 
characterized carboxy-terminal 25 amino-acid region that exclusively binds β-catenin or 
plakoglobin (γ-catenin) and a membrane-proximal region that binds several members of the p120 
subfamily. In general, the cytoplasmic domain of classical cadherin interacts with β-catenin or 
plakoglobin (γ-catenin), which in turn bind α-catenin. α-catenin is attached to the actin cytoskeleton 
directly and/or indirectly.  
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Extracellular structure of classical cadherins Steinberg and McNutt, 1999 
 
In the breast, one of the classical cadherins, P-cadherin (encoded by the gene, CDH3) is expressed 
by myoepithelial cells and these cells adhere to each other via P-cadherins [233]. P-cadherin-/- mice 
undergo precocious development [234], which suggests that loosing of myoepithelial cell junctions 
triggers ductal branching.  
 
Interestingly, the expression of P-cadherin in human breast cancer has been associated with 
aggressive tumor behavior. Around 30% of breast carcinomas show up-regulation of P-cadherin 
[235, 236]. Specifically, P-cadherin is frequently over-expressed in high-grade invasive breast 
carcinomas and enhances migration and invasion of breast cancer cells [237, 238].  
 
Since we observed increased motility in T47D breast cancer cells when treated with Wnt1, the 
reported evidences that up-regulated expression of P-cadherin associates with aggressive breast 
tumor behavior prompted us to examine whether P-cadehrin expression is altered upon Wnt 
stimulation in breast cancer cells. To examine this, T47D cells were ectopically transfected with 
Wnt1-encoding plasmid or empty vector as a control. More than 100 clones from each group were 
pooled after the selection. Interestingly, T47D expressing Wnt1 showed up-regulated P-cadherin 
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RNA level compared to control T47D cells according to microarray analysis (Fig 12A). P-cadherin 
protein level was also confirmed by western blotting. For western experiments, Wnt1- or Wnt5a- 
transfected pools of T47D cell were additionally established. Each pools consists of more than 100 
clones. Western blotting on three independent T47D/Wnt1 pool, three T47D/Wnt5a pool and three 
T47D/control pool showed that P-cadherin level was constantly up-regulated in ectopically 
Wnt1-expressing T47D cells, while control and ectopically Wnt5a-expressing cell did not show 
up-regulated P-cadherin (Fig 12B). This tendency was observed both in confluent cultured cells and 
sparcely spread cells. However the effect was more striking in confluent monolayers (Fig.12C).  
 
P-cadherin level was also examined in ectopically sFRP1-expressing T47D cells. sFRP1-encoding 
vector or empty vector was transfected to T47D cells and two independent sets of pool were made. 
Each pool contains more than 100 clones. Western blotting analysis showed P-cadherin level was 
suppressed upon ectopic sFRP1 expression (Fig.12D). 
 
 
IV. DISCUSSION  
Possibility of targeting WNT signaling pathway in breast cancer 
Aberrant activation of the WNT pathway plays an important role in many types of human cancer. 
Thus, approaches to target the pathway are warranted, although its complexity makes this a difficult 
undertaking [239]. Wnt1 was the first identified oncogene activated by mouse mammary tumor 
virus (MMTV) insertional mutagenesis [240], establishing the potential of aberrant WNT ligand 
expression to promote mammary cancer. We now know that multiple WNT ligands and FZD 
receptors are expressed in primary human breast tumors and breast cancer cell lines [153, 177] [154, 
156], making it difficult to identify an individual ligand/receptor complex that could serve as a 
therapeutic target. However, by using broad antagonists to interfere with WNT/FZD binding, such 
as the cysteine rich domain (CRD) of the FZD8 receptor [241] or sFRP1 [177, 181], the potential of 
targeting WNT binding as a therapeutic approach in breast [177, 181] and other cancers [241, 242] 
has been demonstrated. The results we present here showing that ectopic sFRP1 expression in 
MDA-MB-231 cells significantly blocks their in vivo tumor forming ability support the proposal 
that extracellular antagonists of the WNT pathway might have a role in treating human cancer.  
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Suppressed sFRP1 expression in breast tumor 
Expression of sFRP1 is reported to be lost in a high percentage of primary breast tumors, both at the 
RNA level (>75%) [171, 172] and at the protein level (>40%) [173]. Moreover, methylation of the 
promoter region of the SFRP1 gene was reported both in primary breast tumors (>60%) and breast 
cancer cell lines [170] [174] [175]. Interestingly, loss of sFRP1 protein expression and promoter 
hypermethylation is associated with disease progression and poor prognosis [173] [170]. Since 
aberrant hypermethylation of gene promoters is a major mechanism associated with inactivation of 
tumor-suppressor genes in cancer [162], promoter hypermethylation of SFRP1 gene suggests one 
mechanism that might contribute to WNT pathway activity.  
 
In the current study, we used T47D and MDA-MB-231 human breast cancer cell lines as 
experimental models. It has been reported that SFRP1 is not expressed in these cells by semi 
quantitative real time PCR. Moreover, the promoter region of SFRP1 is reported to be fully 
methylated in MDA-MB-231 and partially methylated in T47D cells [193] [175]. We confirmed 
that T47D, MCF7, BT474 and MDA-MB-231 do not express sFRP1 RNA using quantitative 
RT-PCR and the promoter region of SFRP1 gene in MCF7, BT474 and MDA-MB-231 was 100% 
methylated and that in T47D was partially methylated (Fig 9). These results suggest that suppressed 
sFRP1 expression in breast cancer cell lines is at least partially because of the promoter methylation 
of SFRP1 gene. 
 
WNT signaling and breast tumor cell motility 
We show here that the WNT pathway influences breast tumor cell motility. Various WNT ligands, 
including Wnt1 and Wnt3a have been shown to stimulate cellular migration [183, 184]. Our results 
show that Wnt1 stimulates T47D breast tumor cell motility; conversely sFRP1 mediated blockade of 
endogenous WNT signaling reduces motility of the MDA-MB-231 cells (Figs 1 and 3). To provide 
mechanistic insight into the effects on motility, we show that the activity of RhoA, a GTPase that has 
been implicated in WNT signaling and cell movement [183, 184] is elevated in Wnt1 expressing 
T47D cells (Fig 2). 
 
Rho-family GTPases, including Cdc42, Rac1 and RhoA, are known to play a central role in 
establishing cell polarization and migration [182]. Microinjection of active forms of RhoA rapidly 
induces stress fiber formation in mammalian cells [243] [244]. Stress fibers are bundles of actin 
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filaments that traverse the length of a cell. Stress fibers regulate cell shape by providing mechanical 
rigidity and help to control cell migration and motility by connecting the cytoplasm to the 
extracellular matrix (ECM) via focal adhesions. Namely, Rho regulates eukaryotic cell polarity, 
shape, and migration by controlling stress fibers and focal adhesion formation [245]. RhoA is 
reported to be activated upon canonical WNT stimulation in some contexts. For example, HEK 
293T cells show elevated level of activated RhoA upon treatment with Wnt1 CM [183] and CHO 
cells show pronounced stress fiber formation, RhoA activation and promotion of cell motility upon 
Wnt3a stimulation. Furthermore, the elevated motility induced by Wnt3a was blocked respectively 
by sFRP1 or Rho kinase inhibitor [184]. 
 
In view of cancer cell motility, we also checked the level of P-cadherin as an interesting molecule 
related to cell invasiveness in breast cancer. P-cadherin is one of the classical cadherins, which 
mediate calcium-dependent cell-cell binding when they are localized to the adherents-type junctions. 
In normal adult nonlactating breast tissue, P-cadherin expression is restricted to myoepithelial cells. 
It remains unknown what biological function P-cadherin has in tumor lesions, however, particularly 
in breast tumor, P-cadherin is reported to be able to enhance cell invasion and tumor aggressiveness. 
Several reports have indicated that P-cadherin expression in mammary carcinomas associated with 
poor prognosis in patients [238]. We showed that P-cadherin protein levels were elevated upon the 
ectopic expression of Wnt1 in T47D cells (Fig 12), and cell motility was also promoted in these 
cells (Fig 1). These results suggest that the expression level of P-cadherin is regulated by the 
activation of WNT signaling. These results suggest the possibility that WNT signaling stimulates 
expression of mediators which leads to increased cell motility.  
 
It has been reported that transgenic expression of Wnt1 in the mammary gland of mice results in 
mammary adenocarciomas with metastasis to lymph nodes and lungs [246]. This metastasic 
phenotype might come from the promoted cell motility by activated WNT signaling because WNT 
activation promotes cell motility and P-cadherin expression. Our results suggest the possibility that 
blockade of canonical WNT signaling might be an effective way to target metastatic breast cancer.  
 
Cell proliferation and tumor growth in view of WNT signaling 
We have previously shown that proliferation of the estrogen receptor (ER) positive MCF7 and 
T47D breast tumor cells, and the ErbB2-overexpressing JIMT-1, SKBR3 and BT474 breast tumor 
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cells is decreased following treatment with sFRP1 [177]. It has been reported that many primary 
tumors have low sFRP1 levels [171-173]. Here we tested the impact of ectopic sFRP1 expression in 
the basal-like [72] MDA-MB-231 breast tumor cells. We show that sFRP1 expressing 
MDA-MB-231 display down-regulation of WNT signaling activity, reduced in vitro proliferation 
and a dramatic impairment in their ability to grow as mammary tumor xenografts in nude mice 
(Figs 3, 4). Taken together, these results suggest that blockade of WNT signaling might be a general 
approach to target breast cancer.  
 
Our results suggest that the in vivo effects of sFRP1 on WNT pathway blockade are more striking 
than its in vitro activity. In four independent experiments with the highly sFRP1-expressing 
MDA-MB-231/sFRP1-P1 cells, the time to appearance of the first tumor following their injection 
was consistently longer, in comparison to control MDA-MB-231 cells. Furthermore, tumors 
generated by MDA-MB-231/sFRP1-P1 cells grew more slowly than control tumors, and the number 
of tumor-free mice at the end of each experiment was consistently higher. The mechanisms 
underlying the ability of sFRP1 to impair tumor growth might be tumor cell intrinsic or extrinsic, via 
effects of secreted sFRP1 on tumor-associated cells. We examined tumor associated vessels, which 
are obvious candidates based on the reported ability of sFPR1 to block in vivo neovascularization 
[187], however, we have no evidence that vessel number or functionality are affected by expression 
of sFRP1 in the MDA-MB-231 cells (Fig 5). We favor the hypothesis that the effects of sFRP1 are 
mainly on the tumor cells themselves via blockade of WNT pathway activity.  
 
Our in depth transcriptome analysis resulted in the identification of a panel of genes whose 
expression is altered by blockade of WNT signaling. The genes were classified as those that are 
altered in vivo and in vitro by sFRP1 expression, and those that are only affected in vivo in 
sFRP1-expressing tumors. Considering the first category, there were 1753 probesets (1246 genes) 
whose signals were significantly changed in the tumors arising from MDA-MB-231/sFRP1 cells 
compared to tumors arising from control cells. The same analysis performed on in vitro cultured 
samples revealed 428 probesets (332 genes). Only 69 probesets (54 genes) overlapped between the 
two analyses clearly demonstrating the important effect of the cellular environment on the 
transcriptome.  
 
After filtering out genes whose expression was only altered in vivo, in the sFRP1 expressing tumors, 
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we analyzed 106 down-regulated genes and 62 up-regulated genes for targets that might contribute 
to tumor growth suppression (Supp Table 1 lists the genes and their fold change). Two of them, 
CCND1 and CDKN1A, that were down-regulated and up-regulated, respectively, were also 
validated at the protein level and are very likely contributing to the suppressed tumor outgrowth. 
 
Cyclin D1, which is encoded by the gene CCND1, plays an important role in G1-S transition during 
cell cycle progression. Binding of Cyclin D1 to its kinase partners, the Cyclin dependent kinases 4 
and 6 (CDK4/6), results in the formation of active complexes that phosphorylate the Retinoblastoma 
tumor suppressor protein (RB). Hyperphosphorylation of RB results in the release of RB-sequesterd 
E2F transcription factors and the subsequent expression of genes required for entry into S-phase. 
Furthermore, Cyclin D1 has also been shown to act as a cofactor for several transcription factors 
[247] [248]. Importantly, CCND1 is one of the WNT target genes [109, 110, 249]. Namely, the 
CCND1 promoter has a consensus LEF-1 binding site [110] and in some colon cancer cell lines [109], 
but not others [250], its transcription is responsive to β-catenin/TCF activation. It is possible that in 
the MDA-MB-231 model Cyclin D1 is a direct WNT pathway target.  In our experiment, one of the 
CCND1 probesets revealed less CCND1 RNA in both in vivo and in vitro MDA-MB-231/sFRP1 cells 
(Supp Table 2 and Supp Fig 5). With the other probeset, CCND1 was only decreased in vivo in 
MDA-MB-231/sFRP1 tumors (Fig 7C). However, Cyclin D1 protein was only down-regulated in 
vivo in MDA-MB-231/sFRP1 tumors (Fig 8), suggesting that transcriptional as well as 
post-transcriptional regulatory mechanisms play a role in influencing the final Cyclin D1 protein 
levels (Fig 8). 
 
Cyclin D1 can also be induced by extracellular signal-regulated kinases through the cascade 
composed of Ras/Raf/mitogen-activated protein kinase (MAPK) kinase (MEK)/extracellular 
signal-regulated kinase (ERK) [251]. Conversely, inhibition of the Ras pathway inhibited CCND1 
gene expression [252]. Since MDA-MB-231 cell line has an activating k-ras mutation [186], the 
“Ras/Raf/mitogen-activated protein kinase (MAPK) kinase (MEK)/extracellular signal-regulated 
kinase (ERK) cascade” should theoretically be constitutively activated in MDA-MB-231 cells. In 
agreement with this, we have observed that sFRP1 expressing cells maintain high P-ERK levels (Fig 
3A). The fact that Cyclin D1 expression can still be suppressed by sFRP1 in MDA-MB-231 cells 
implies the dominancy of WNT signaling to induce CCND1 in breast cancer cell lines. 
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On the other hand, p21Cip1, a protein encoded by CDKN1A gene, is a well-characterized CDK 
inhibitor that belongs to the Cip/Kip family. p21Cip1 mainly inhibits the activity of Cyclin/CDK2 
complexes and negatively modulates cell cycle progression [253]. In addition, p21Cip1 can bind to 
proliferating cell nuclear antigen thereby blocking DNA synthesis [254]. Based on the positive role 
of Cyclin D1 in cell cycle progression and the function of p21Cip1 to negatively modulate cell cycle 
progression, the suppression of tumor growth in vivo upon sFRP1 expression is likely to be caused 
by cell cycle arrest.  
 
We also looked specifically at known WNT pathway target genes 
(http://www.stanford.edu/~rnusse/pathways/targets.html). Among these, there are 16 genes where at 
least one of the probesets shows a tendency for suppression in MDA-MB-231/sFRP1 cells both in 
vitro and in vivo (Supp Table 2 and Supp Fig 5). c-Myc, a well described target of canonical WNT 
signaling [111, 190, 250], was not decreased in the MDA-MB-231/sFRP1 cells. However, tumors 
resulting from injection of MDA-MB-231/sFRP1 cells have low c-Myc protein levels (Fig 6).  
 
The protooncogene c-MYC, which encodes a transcription factor playing a major role in the 
regulation of normal cell proliferation, is aberrantly expressed in many human cancers [255]. Myc 
is a member of the bHLHZip4 family of transcription factors which, when dimerized with its 
partner Max, binds to specific DNA sequences resulting in the transcriptional regulation of target 
genes involved in the control of many aspects of cellular physiology including growth and 
proliferation [256-262]. 
  
In normal cells, c-MYC mRNA and c-Myc protein are both short-lived [258]. Thus, Myc expression 
is highly regulated at multiple levels in a normal cell. In contrast, deregulated c-Myc expression is 
quite prevalent in human tumors. In breast cancer, it has been reported that approximately 40-45% 
of primary breast tumors show overexpression of c-MYC protein [263, 264] and around 20% of all 
breast tumors show amplification of the c-MYC gene [264, 265]. Furthermore, examination of 
c-MYC mRNA has suggested the possibility of aberrant regulation of c-MYC expression on the 
transcriptional level [266]. Interestingly, although our experiments showed that c-Myc protein was 
decreased in tumors arising from MDA-MB-231/sFRP1 cells, qRT-PCR analysis and microarray 
analysis revealed that the regulation of c-Myc protein level upon the ectopic expression of sFRP1 in 
the tumor was not accompanied with changes in the c-MYC mRNA level. This suggests that 
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activating WNT signaling pathway might not only target c-Myc transcription at least in some 
models, but could also protect the c-Myc protein from degradation and/or might be implicated in the 
translational control of c-Myc. 
 
It is also reported that c-Myc can stimulate the transcription of D-type cyclins [267, 268]. 
Together with these reports, our data suggest that there might be a synergistic effect of 
Myc-mediated Cyclin D1 transcription and β-catenin mediated Cyclin D1 transcription by 
the activation of WNT signling pathway in MDA-MB-231 breast cancer cells. On the other 
hand, it is known that CDKN1A expression is suppressed by the c-Myc/Miz-1 heterodimer 
[269-271]. Furthermore, in breast cancer, c-Myc has been shown to be a negative regulator 
of p21Cip1 [272]. Thus, the increase in p21Cip1 that is only observed in vivo in the sFRP1 
expressing tumors might be due to the dramatic c-Myc reduction observed in the same 
tumors (Fig 8).  
 
Since c-Myc can induce the synthesis of CyclinD1 and suppress the transcription of CDKN1A, the 
decrease of c-Myc protein might be a pivotal event caused by ectopic sFRP1 expression and might 
contribute to the dramatic suppression of tumor formation and tumor growth observed in vivo. 
Furthermore, c-Myc has recently been shown to be the crucial mediator of early stage intestinal 
neoplasia arising in APC mutant mice [190], implying that c-Myc plays critical role downstream of 
Wnt/β-catenin signaling leading to tumorigenesis. Nevertheless our Myc-rescue experiment did not 
result in total recovery of tumor formation, over-expression of c-Myc partially rescued the impaired 
tumorigenesis resulting from MDA-MB-231/sFRP1 cells (Suppl Fig 3). It is possible that the 
ectopic expression level of c-Myc was not high enough to rescue tumor formation completely. 
However, the fact that only a slight over-expression of c-Myc rescued the tumorigenesis in some of 
the cases suggests the importance of the role played by c-Myc under the autocrine activation of 
WNT signaling in breast cancer.   
 
Further experiments will be needed to confirm whether c-Myc plays a pivotal role in the tumor 
growth suppression in MDA-MB-231/sFRP1 xenograft model. However, it is clear that all three 
proteins, Cyclin D1, p21 and c-MYC, have important roles in cell cycle progression. In colorectal 
cancer models, it has been reported that sustained down-regulation of canonical Wnt/β-catenin 
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signaling results in a cell cycle arrest [250]. Our results in the MDA-MB-231 breast tumor model 
are similar since sFPR1-expressing tumors showed less BrdU incorporation in comparison to 
controls tumors. The results from our study suggest the decrease in S-phase activity is caused by the 
regulated levels of Cyclin D1, p21Cip1 and c-Myc.  
 
In addition to these molecules known to be cell cycle modulators, we identified additional 
transcripts in the microarray analyses that might also contribute to the decreased proliferation of 
sFRP1 expressing cells, including β1 integrin (CD29) and its ligand, fibronectin (FN1). The RNA 
levels of both CD29 and FN1, the latter a known WNT pathway target (Supp Table 2) are 
suppressed in MDA-MB-231/sFRP1 cells, in vitro and in vivo. We have previously shown that 
siRNA mediated knock-down of β1 integrin in MDA-MB-231 cells causes an increase in p21Cip1 
expression and a decrease in proliferation [273].  FN1, which was shown to be down-regulated 
following expression of sFRP3 in a prostate cancer model [242], has also been shown to affect 
cancer cell proliferation [274]. This growth signaling via FN1 and β1 integrin might also a mediator 
of the growth promotion triggered by the activated autocrine WNT pathway. 
 
Apoptosis is not important in MDA-MB-231/sFRP1 experimental model 
Despite the fact that the microarray analysis revealed that proapoptotic genes are up-regulated in 
sFRP1 expressing cells, including the FAS receptor and its ligands, TNFSF12/13 and TNFSF15, we 
could not detect increased levels of apoptotic MDA-MB-231/sFRP1 tumor cells. Since many 
inhibitors of apoptosis (IAP) were expressed in these tumors, including BIRC2 (cIAP1), BIRC3 
(cIAP2), BIRC4 (XIAP), BIRC5 (survivin), BIRC6 (apollon) and BIRC7, and only BIRC6 
(apollon) levels decreased in sFRP1 expressing cells (from microarray analysis), it is possible that 
the multiple IAPs contribute to the survival of the MDA-MB-231/sFRP1 tumors. 
 
WNT signaling and tumor progenitor cell phenotype 
CD44, CD24 and CD29 are surface markers used for the selection of progenitor cells [204-206, 
213]. The CD44high/CD24low population is associated with breast tumor progenitor cells and normal 
mammary epithelial stem cells [204, 205]. Our microarray analysis showed that CD44, a WNT 
pathway target gene [210] was down-regulated (Supp Table 2 and Supp Fig 5), while CD24 was 
increased in MDA-MB-231/sFRP1 cells, in vitro and in vivo. This was confirmed by FACS analysis 
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of protein expression on cultured cells (Fig 10). As mentioned above, CD29 (β1 integrin) was also 
decreased in the sFRP1 expressing cells. High CD29 levels have been associated with mammary 
stem cell potential, and interestingly, CD29high population is expanded in mammary tissue from 
MMTV-WNT mice [213].  
 
There is increasing evidence that the WNT pathway regulates self-renewal and fate of breast cancer 
stem cells [275]. The results we present here suggest that autocrine WNT signaling might regulate 
the tumor initiating cells in the MDA-MB-231 model of basal breast cancer and this may be one of 
the reasons that ectopic sFRP1 expression has such a striking effect on the tumor outgrowth 
potential of the cells.  
 
Link between EMT and tumor initiating cells 
Interestingly, there is a report showing that the expression of stem cell markers and the increased 
ability to form mammospheres result from the induction of epithelial-mesenchymal transition 
(EMT) in human mammary epithelial cells [206]. On the other hand, stem-cell like cells isolated 
from human mammary epithelial cell culture had undergone EMT [206]. These observations 
illustrate a direct link between the EMT and the gain of epithelial stem cell properties. 
 
EMT, which is the loss of epithelial and the gain of mesenchymal characteristics, is an important 
step leading to invasive cancer cells. Epithelial cells undergo a developmental switch from the 
polarized, epithelial phenotype to a highly motile fibroblastoid phenotype [276]. The process of 
EMT, whereby epithelial cells lose cell–cell contact, undergo remodeling of the cytoskeleton, and 
manifest a migratory phenotype has been implicated in the conversion of early-stage tumors to 
invasive malignancy [277]. A defining feature of EMT is the loss of E-cadherin expression and gain 
of fibronectin and vimentin expression [278], [279]. In addition to the disorganization of 
E-cadherin-ß-catenin complexes, the de novo expression of vimentin is a mechanism frequently 
associated with an EMT and the metastatic conversion of epithelial cells. 
 
Vimentin is a type III intermediate filament normally expressed in cells of mesenchymal origin 
[280]. On the other hand, vimentin can also be expressed in epithelial cells involved in physiological 
or pathological processes requiring epithelial cell migration, suggesting that the expression of 
vimentin is required for epithelial cells to accomplish EMT. Vimentin has indeed been described in 
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migratory epithelial cells involved in embryological and organogenesis processes, in placentation, in 
wound healing, or in tumor invasion [281] [282] [283] [284]. Also, vimentin antisense transfection 
in vimentin-expressing breast cell lines including MDA-MB-231 was shown to reduce their in vitro 
invasiveness or migration, strongly emphasizing a functional contribution of vimentin to epithelial 
cell invasion/migration [284, 285]. In the same way, an impaired wound healing has been observed 
in vimentin knockout mice [286] [287]. These observations suggest that vimentin expression 
promotes EMT and cell motility. 
 
The MDA-MB-231 cell line is highly motile and invasive, carries an activated Ki-ras allele and 
appears phenotypically to have undergone EMT [186] [288] [289]. However, this mesenchymal 
phenotype of MDA-MB-231 cells seems to be reverted upon the ectopic expression of sFRP1. 
Namely, in our study, although E-cadherin mRNA levels were not changed, the mRNA level of the 
other EMT markers, fibronectin and vimentin were suppressed upon the ectopic expression of 
sFRP1 both in cultured MDA-MB-231 cells and xenograft tumors (Supp Fig 7). We also observed 
the down regulated cell motility following ectopic sFRP1 expression in MDA-MB-231 cells (Fig 
3D). These observations suggest that the ectopic expression of sFRP1 might let MDA-MB-231 cells 
undergo mesenchymal-epithelial transition (MET) and eventually suppress cell motility. 
 
Possible mechanisms behind breast tumor growth suppression by interfering with 
antocrine WNT pathway 
We observed that the ectopic expression of sFRP1 in MDA-MB-231 cells has a big impact on 
xenograft tumor outgrowth and this effect is most likely via cell cycle arrest. However, I think one 
of the most pivotal mechanisms behind this effect might be the fact that the interference with WNT 
signaling via sFRP1 expression affects tumor initiating cell phenotype.  
 
MDA-MB-231 is a basal type breast cancer cell line [72]. In the breast, the term “basal” has 
acquired two meanings. In one context it has become the word having the same meaning of “breast 
myoepithelium” and in the other context, it defines a specific subpopulation of “basal” cytokeratins, 
CK5, CK14 and CK17, expressing cells [6]. However, in the latter meaning, the origin of “basal” 
cell is still controversial. Because most basal-like breast tumors still express luminal cytokeratin 
8/18, suggesting that basal-like cancers also possess characteristics of luminal lineage. Furthermore, 
several classic myoepithelial markers were rarely expressed in basal-like tumors. These findings 
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provide evidence against the hypothesis that basal-like breast cancers are derived directly from 
myoepithelial cells. Instead, these findings could suggest that basal-like breast cancer cells are 
differentiated directly from a stem cell [67].  
 
According to our microarray experiment, MDA-MB-231 cells also express high levels of luminal 
cytokeratines 8/18 (Supp Fig 6), which is in line with the hypothesis that the origin of these cells is 
a stem cell. This hypothesis is currently still under the discussion, however, is very interesting 
together with our observations from MDA-MB-231 cells. We observed two important facts, 1; 
interfering with autocrine WNT signaling pathway in MDA-MB-231 cells suppresses the cancer 
stem cell phenotype and 2; at the same time, interfering with autocrine WNT signaling pathway in 
these cells leads to the phenotype which seems to have undergone MET. Since there is a direct link 
between cancer stem cell phenotype and EMT [206], these two observations suggest that interfering 
with autocrine WNT pathway “reverts” cancer stem cell phenotype of MDA-MB-231 cells or 
“decreases” the cancer stem cell population in MDA-MB-231 cells. 
 
Reverting cancer stem cell phenotype and/or decreasing cancer stem cell population by interfering 
with autocrine WNT pathway could be broadly efficient to treat breast cancer patients because 
suppressing cancer stem cell phenotype can allow cancer cells to become more sensitive to 
chemotherapeutics. Cancer stem cells are hard to eliminate by chemotherapeutics due to their 
elevated activity of drug efflux [222, 225]. Increasing evidences suggest that stem/progenitor cells 
evade cell death by a number of mechanisms, such as quiescence and drug-efflux conferred by the 
ABC-family of membrane transporters [222]. In our experiments, the drug-efflux activity was 
suppressed upon the sFRP1 CM treatment in MDA-MB-231 cells (Fig.10D) and the expression of 
ABCA2, a member of the ABC super family whose expression has been correlated with drug 
resistance [226] [227] [228], was suppressed upon sFRP1 expression both in vitro and in vivo (Fig 
10E).  
 
It is difficult to target cancer stem cells not only because of their efflux activity, but also due to the 
fact that they are de-differenciated. For example, after the tamoxifen treatment to target ER+ breast 
tumors, even if a turmor seems to have regressed, it can relapse after a while because there might 
had been a small number of cancer stem cells which can grow in an ER signaling independent 
manner. MDA-MB-231 cells are known to be ER negative [72]. However, according to our 
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microarray analysis, one of the probesets showed slightly increased signal of the gene coding ERα 
upon the ectopic expression of sFRP1 in MDA-MD-231 cells (data not shown). Furthermore, 
ectopic expression of Wnt1 in T47D cells, which is a ER+ breast cancer cell line [72], leads to a 
slight decrease of ERα RNA expression according to the microarray analysis (data not shown). 
These transcriptional alterations of ERα are very slight and further experiments will be needed to 
confirm them. However, it is quite interesting because it might be showing the fact that activating 
WNT signaling can de-differenciate breast cancer cell phenotype and interfering with the autocrine 
WNT signaling activity can re-differenciate breast cancer cell phenotype. 
 
Final statements 
To conclude, interfering with autocrine WNT pathway by sFRP1 not only suppresses breast tumor 
outgrowth by cell cycle arrest, but also might cause breast tumor cells to become more sensitive to 
chemotherapies by suppressing their drug-efflux ability and by leading them to re-differenciate. 
One important question which should be answered is whether established breast tumors regress 
upon de novo expression of sFRP1 or sFRP1 treatment. For this, MDA-MB-231 cells infected with 
sFRP1 coding sequence under tetracycline responsible promoter will be needed. Without 
doxycycline, these cells do not express sFRP1. After letting these cells grow in 
immunocompromised mice as xenograft, sFRP1 expression can be induced by feeding them with 
doxycycline. If tumor regresses after they have doxycycline, it confirms the hypothesis that treating 
breast cancer patients with sFRP1 is a good target therapy. Furthermore, our observations suggest 
the efficiency of interfering with autocrine WNT signaling in combination with chemotherapy to 
treat breast tumor patients, because interfering with autocrine WNT pathway seems to cause breast 
cancer cells to become more sensitive to chemotherapeutics. For example, treatment with purified 
sFRP1 or humanized antibody which can block WNT receptors at the same time of treatment with 
tamoxifen for ER+ breast cancer patients might bring better outcome compared to tamoxifen 
treatment alone. 
 
In this thesis, I showed that sFRP1 mediated WNT pathway blockade strongly blocks the in vivo 
mammary tumor forming potential of MDA-MB-231 breast cancer cells. The results presented here 
suggest that interference with WNT signaling at the ligand-receptor level may be a valid therapeutic 
approach in breast cancer. It is just a starting point to establish or to make a way to establish a novel 
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approach to target breast tumor, however, I wish this study becomes a start for me to contribute to 
release patients who are suffering from various cancers some day in the future. Every year, many 
people are losing their lives because of cancer including breast cancer. This is not only a tragedy, but 
also a considerable loss for our society. I have been researching on breast cancer throughout my PhD 
study and I am also going to continue cancer research in the future. Throughout my research life, I 
wish I can contribute to solving at least one piece of the complicated puzzle of tumor biology. I would 
be eventually very happy if this one piece could help us humans with overcoming cancer.   
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Supplemental table 1A 
Gene fold down-regulation upon sFRP1 expression 
FGF5 4.09 
BDNF 4.03 
FBXO25 3.84 
BDNF 3.30 
FGF5 3.28 
DEAF1 2.97 
DLC1 2.96 
DKFZp313A2432 2.77 
APEH 2.70 
ZNF289 2.69 
FGF5 2.65 
TEX261 2.65 
GALNT10 2.65 
SLC39A4 2.60 
ARHGEF10 2.60 
TSPAN4 2.58 
LYPD6 2.54 
EPS8L2 2.45 
MFHAS1 2.40 
KLF11 2.40 
FXC1 2.38 
PTPMT1 2.30 
C9orf140 2.30 
MFHAS1 2.26 
TOLLIP 2.22 
PTPN18 2.21 
FLJ11236 2.20 
EIF2B4 2.20 
ANTXR1 2.19 
MAPKAPK3 2.17 
HOMER3 2.16 
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TOLLIP 2.16 
MAPKAPK3 2.14 
KIAA0652 2.09 
HOMER3 2.09 
TGOLN2 2.08 
CUGBP2 2.07 
LOC283267 2.04 
RNF141 2.04 
MAGEA3 2.03 
SCD 2.03 
COMTD1 2.02 
CCL28 1.99 
FLJ13305 1.99 
GSTM4 1.98 
MAGEA6 1.97 
POLE4 1.96 
RNH1 1.95 
TSTA3 1.95 
POLE4 1.95 
GRK6 1.94 
KBTBD4 1.94 
TGOLN2 1.94 
NUP98 1.93 
NAP1L4 1.93 
NPAS2 1.92 
SUSD1 1.90 
THUMPD3 1.88 
NAP1L4 1.85 
MCART1 1.85 
BOK 1.85 
RIC8A 1.85 
TALDO1 1.84 
MTA3 1.84 
B3GNT2 1.83 
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B3GNT2 1.83 
MPHOSPH10 1.83 
SGK3 1.83 
FAM125A 1.83 
CRIM1 1.82 
EIF2B4 1.81 
HRAS 1.80 
PDLIM5 1.80 
AP2A2 1.80 
PEX13 1.80 
ALKBH3 1.79 
ARHGAP1 1.78 
SERTAD2 1.76 
C19orf12 1.76 
STOML1 1.76 
RAP2B 1.74 
ASB1 1.74 
SMEK2 1.74 
LEPROTL1 1.73 
SAAL1 1.73 
PSMD13 1.70 
C6orf108 1.69 
CCDC75 1.67 
ASH2L 1.65 
ING5 : LOC727773 1.65 
MOBKL1B 1.64 
SUMO3 1.64 
IQGAP1 1.63 
PI4K2B 1.63 
LOC728944 : THAP4 1.62 
ALDH3A2 1.62 
PSME4 1.62 
RAB1A 1.62 
RFXANK 1.61 
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AKT3 1.61 
RNASEH1 1.60 
POLR2L 1.60 
C9orf142 1.60 
MRPL23 1.59 
AKTIP 1.59 
SETMAR 1.58 
C11orf17 1.57 
SGCB 1.57 
ANAPC1 1.57 
MOBKL1B 1.57 
SLC4A1AP 1.56 
KIAA0652 1.55 
TMEM9B 1.55 
MRPL53 1.55 
C5orf30 1.54 
C2orf4P : MEMO1 1.54 
PSMC3 1.53 
AUP1 1.52 
SMEK2 1.51 
CCND1 1.51 
CENPA 1.51 
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Supplemental table 1B 
Gene fold up-regulation upon sFRP1 expression 
SFRP1 51.13 
PAEP 30.29 
PRSS1 : PRSS2 : PRSS3 : TRY6 29.23 
SERPINA3 27.59 
ECSM2 26.93 
TRY6 26.15 
PRSS1 25.21 
ECSM2 23.03 
SERPINA1 20.26 
SLC2A10 19.62 
OBP2A : OBP2B 12.72 
SERPINA1 11.04 
LOC149773 8.94 
OAS2 8.12 
GPR87 7.35 
TMEM178 6.76 
FOLR1 6.16 
LTBP2 6.06 
TIE1 5.81 
WFDC10B 5.74 
APCDD1L 5.26 
RARRES3 5.25 
CLU 5.24 
METTL7A 5.15 
CTSS 5.11 
DTX3 5.07 
AIM2 4.97 
OBP2A 4.91 
TMPRSS2 4.85 
BHLHB3 4.82 
GLDN 4.80 
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TAGLN3 4.72 
CLU 4.62 
LOC286299 4.40 
HOXB3 4.24 
CASP1 4.24 
CLU 3.99 
APOBEC3F : APOBEC3G 3.91 
IGFBP6 3.84 
SSPN 3.77 
HERC6 3.72 
FAM125A 3.70 
ANK3 3.66 
LTBP2 3.57 
CTSS 3.47 
CASP1 : COP1 3.20 
FLJ20035 3.07 
KLHL3 3.03 
CYP2E1 3.02 
SULT1A3 : SULT1A4 3.02 
CDRT4 3.00 
ABCC3 2.84 
USP52 2.75 
PER1 2.72 
SLC39A11 2.71 
ITGA5 2.56 
C17orf60 2.43 
FXYD5 2.07 
TAPBPL 2.02 
ARHGAP26 1.98 
FXYD5 1.98 
KRT79 1.96 
PRIC285 1.90 
TIAM1 1.86 
PECAM1 1.77 
 101
MMD 1.75 
CPD 1.70 
CDKN1A 1.66 
B4GALT5 1.64 
CPD 1.64 
 
Supplemental table 2 
NRCAM 
PTGS2 (COX2) 
PPARD  
RUNX2 
FZD7 (Frizzled7) 
LEF1 
CCND1 (CyclinD1) 
EDN1 (Endothelin1) 
CD44  
RHOU (Ras homolog gene family, member U) 
AXIN2 
JUN 
STRA6 
PLAUR (Plasminogen activator) 
TCF4 
FN1 (Fibronectin1) 
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VI. FIGURE LEGENDS 
Figure 1 
Wnt1 promotes T47D cell migration  
(A) Upper panel; Confluent monolayers of T47D cells were scratched and the medium was changed 
to Wnt1 CM or control CM and pictures of wounded edges were taken 3 hours later. Bar-graph; 
Confluent monolayers of T47D cells were scratched and the medium was changed to Wnt1 CM, 
Wnt1 CM + sFRP1 or control CM. For Wnt1 CM + sFRP1, ¼ volume of purified sFRP1 [7] was 
added to the CM. For the other conditions, the same volume of PBS was added to the CM. Nine 
randomly-chosen wound edges per condition were monitored 3 hours and 7 hours after scratching. 
The average recovered area (arbitrary unit; pixels on the computer screen) +/- SEM was calculated. 
**p<0.01 (B) Wnt1 levels in a clone and a pool of T47D/Wnt1 expressing cells (clone 1 and P1) 
and in control cells were measured in a western analysis with a Wnt1 specific antiserum. (C) 
Confluent monolayers of T47D/Wnt1 clone 1 and a control (left bar graph) or T47D/Wnt1 P1 and a 
control (right bar graph) were scratched and a wound healing assay was performed in DMEM plus 
10% FCS. Nine randomly-chosen wound edges per condition were monitored 3 hours after 
scratching. Average recovered areas (arbitrary unit) +/- SEM were calculated. ** p<0.01 
 
Figure 2 
Elevated RhoA activity in Wnt1 expressing T47D cells  
(A) T47D cells were seeded on cover glasses and stimulated by Wnt1 CM or control CM for 30 
minutes, then fixed and stained with phalloidin to visualize actin. Bars: 20 microns. (B) A GST-C21 
(Rhotekin) pull-down assay was performed on lysates of the T47D/Wnt1 P1 and a control pool. The 
level of GTP-RhoA bound to the beads and the total RhoA in the lysate were determined by a 
western analysis with a RhoA antibody. The ratio of: GTP-RhoA/total-RhoA is 0.2408 in 
T47D/Wnt1-P1 and 0.0616 in T47D/control-P1 cells.    The quantification was done using 
ImageQuant TL (GE Healthcare).  
 
Figure 3 
Ectopic expression of sFRP1 in MDA-MB-231 breast cancer cells 
(A) A western analysis was performed on lysates of three MDA-MB-231/sFRP1 clones and three 
MDA-MB-231/control clones and the levels of active β-catenin, α-tubulin and DVL 1-3 were 
determined with specific antisera. Myc-tagged sFRP1 was detected with a Myc specific antiserum. 
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Lower panel; Level of total ERK1/2 and P-ERK1/2 in MDA-MB-231/sFRP1 clone and in 
MDA-MB-231/control clone. (B) The level of Myc-tagged sFRP1 in two pools of 
MDA-MB-231/sFRP1 cells was determined in a western analysis using a Myc specific antiserum. 
α-tubulin levels served as a control. P1 is a mixture of the 3 clones shown in panel A; P2 was 
generated from >100 sFRP1 infected clones. (C) MDA-MB-231/sFRP1 P1 and P2 and control pools 
P1 and P2 were seeded on 6-well dishes (200000 cells/well) in DMEM 10% FCS and cells were 
counted after 3 days. Left: sFRP1-P1 and control. Right: sFRP1-P2 and control. 3 wells per 
condition. Average cell numbers were calculated +/- SEM. ** p<0.01, * p<0.05 (D) Confluent 
monolayers of MDA-MB-231/sFRP1-P1 cells and control-P1 cells were scratched, the medium was 
changed to Wnt1 CM or control CM and 3 hours later the recovered areas were calculated on 9 
randomly chosen wound edges. The results are presented in arbitrary units. Average recovered area 
were calculated +/- SEM. ** p<0.01, n.s.=not significant (p>0.05).  
    
Figure 4 
Ectopic expression of sFRP1 in MDA-MB-231 cells suppresses in vivo tumor formation 
MDA-MB-231/sFRP1-P1 cells and control cells (1x106) (A) and MDA-MB-231/sFRP1-P2 cells 
and control cells (1x106) (B) were injected into mammary fat pads of Balb/c nude mice and tumor 
formation and growth were monitored. Average tumor volume (left graph) and % of tumor free 
mice (right graph) are shown. P1: Left: p<0.01 (Two-way RM ANOVA), Right: p=0.0106 (log rank 
test); P2: left: * p<0.05 on day 19, Right: p=0.026 (log rank test). Insert; A western analysis was 
performed on tumor lysates to check the Myc-tagged sFRP1 and endogenous DVL3 status at the 
end of the experiment. Representative pair of tumor lysates to detect Myc-tagged sFRP1 and lysates 
of 3 sFRP1-expressing and 2 control tumors to check DVL3 status are shown here. 
 
Figure 5 
Analysis of proliferation and tumor angiogenesis in MDA-MB-231/sFRP1 xenografts  
(A) Mice bearing sFRP1-P1 or control MDA-MB-231 tumors were injected with BrdU and two 
hours later they were sacrificed. Tumors of similar weight from each group were sectioned and 
stained with an anti-BrdU antibody (left panel) and BrdU positive nuclei and total nuclei were 
counted in nine randomly chosen areas from each section. Bar graph (right panel) shows the 
quantification +SEM. ** p<0.01, Bar=250 microns (B) Functional blood vessels in tumor-bearing 
mice were visualized by injecting FITC-lectin into tail veins 5 min before sacrificing. Tumor 
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sections were made and stained for CD31, an endothelial cell marker to visualize whole blood 
vessels. Total area, FITC+ area and CD31+ area were measured using IMARIS software (Bitplane). 
Left bar graph: CD31+ area vs total area is presented (5 sFRP1 expressing and 8 control tumors). 
Right bar graph: FITC+ area vs CD31+ area is shown (3 sFRP1 expressing and 5 control tumors). 
+SEM, n.s.=not significant 
 
Figure 6 
c-Myc expression in MDA-MB-231/sFRP1- and control- tumors and cell lines 
(A) qRT-PCR analysis for c-Myc RNA levels in tumor lysates from 6 sFRP1+ tumors and 5 control 
tumors (left bar graph) and cell lysates from the 3 in vitro cultured MDA-MB-231/sFRP1 clones 
and the 3 control clones shown in Fig 3A (right bar graph). Average is shown. +SEM, n.s.=not 
significant (B) Left; sFRP1 and c-Myc levels were analyzed in lysates prepared from 6 
MDA-MB-231/sFRP1-P1 tumors and 2 MDA-MB-231/control-P1 tumors. Right; Lysates of 
cultured MDA-MB-231/sFRP1-P1 cells and MDA-MB-231/control-P1 cells were also subjected to 
a western analysis to check c-Myc levels. Both using c-Myc antiserum. α-tubulin serves as a 
standard. 
 
Figure 7 
Microarray analysis comparing gene expression profiles generated from tumors and from in 
vitro cultured cells 
(A) y-axis- 135 probesets (106 genes) showing low expression in sFRP1+ tumors and 
moderate-high expression in control tumors, and in vitro cultured sFRP1+ and control cells. (B) 
y-axis- 84 probesets (62 genes) showing high expression in sFRP1+ tumors and low expression in 
control tumors, and in vitro cultured sFRP1+ and control cells. (A & B) From left to right, columns 
represent 6 sFRP1+ tumors, 5 control tumors, 3 MDA-MB-231/sFRP1 clones and 3 
MDA-MB-231/control clones (shown in Fig 3A). Highly-expressed genes are indicated in red, 
moderately-expressed genes are indicated in black and lower-expressed genes are indicated in green. 
(C) Normalized gene expression of CCND1 (Cyclin D1) and CDKN1A (p21Cip1) in 
MDA-MB-231/sFRP1-P1 tumors, MDA-MB-231/control-P1 tumors, MDA-MB-231/sFRP1-P1 in 
vitro cultured cells and MDA-MB-231/control-P1 cultured cells.   
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Figure 8 
Detection of Cyclin D1 and p21Cip1 in tumors and in cultured cells 
(A) Tumor sections taken from mice bearing MDA-MB-231/sFRP1-P1 and control tumors were 
stained with a Cyclin D1 specific antiserum. Signal intensities, shown in the bar graph, reflect data 
collected from 6 MDA-MB-231/sFRP1-P1 tumors and 8 control tumors. +SEM, * p<0.05 (B) 
Cyclin D1 was detected in lysates from in vitro cultured MDA-MB-231/sFRP1-P1 cells and control 
cells by immunoblotting. Right bar graph; Expression levels of Cyclin D1 in cultured cells were 
quantified from 3 MDA-MB-231/sFRP1 clones and 3 control clones (shown in Fig 3A). Average is 
shown. +SEM, n.s.=not significant (C) p21Cip1 was detected in tumor lysates prepared from a 
representative MDA-MB-231/sFRP1-P1 tumor and a control tumor. Lysates from in vitro cultured 
MDA-MB-231/sFRP1-P1 and MDA-MB-231 control cells had no detectable p21Cip1.  Lysates 
from MCF7 breast tumor cells and MCF7 with siRNA mediated p21Cip1 KD served as positive and 
negative controls, respectively (+CTRL and -CTRL). All lysates are 40ug per lane. α-tubulin serves 
as a standard. (D) Bar graph: Expression levels of p21Cip1 in tumor lysates were quantified from 5 
sFRP1+ tumors and 5 control tumors with Odyssey software (LI-COR biosciences). +/- SEM, 
**p<0.01 
 
Figure 9 
sFRP1 expression and the methylation status of sFRP1 gene promoter in a panel of breast 
cancer and normal breat cell lines 
(A) sFRP1 expression was examined in a panel of breast cancer cell lines and normal MCF10A 
breast cell line using qRT-PCR. The expression level of sFRP1 was normalized with that of 
beta-actin and indicated in the relative values in which the sFRP1 expression level of HCC1937 cell 
is set as “100”. The ectopically sFRP1 expressing MDA-MB-231/sFRP1 cell serves as a positive 
control. Experiment was duplicated (shown in dark blue and light blue). (B) Methylation status of 
the sFRP1 promoter region was examined by bisulfite sequencing. The three cell lines on the left 
are sFRP1 negative cell lines and the five cell lines on the right are sFRP1 positive cell lines. If the 
sFRP1 promoter region is methylated, a band appears in the lane indicated by “M”, if unmethylated, 
a band appears in the lane indicated by “U”. 
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Figure 10 
sFRP1 suppresses the tumor initiating cell phenotype 
(A) RNA expression of CD24 and CD44 by microarray analysis. From left to right, RNA from 
tumor lysates arising from MDA-MB-231/sFRP1-P1, tumor lysates arising from 
MDA-MB-231/control-P1, cultured MDA-MB-231/sFRP1-P1 cells and cultured 
MDA-MB-231/control-P1 cells. (B) FACS analysis using the specific antisera against CD24 and 
CD44 to see the surface expression of CD24 and CD44 in cultured MDA-MB-231/sFRP1-P1 cells 
and cultured MDA-MB-231/control-P1 cells. (C) Sox2 expression was majored in three individual 
MDA-MB-231/sFRP1 clones and a MDA-MB-231/control clone by RT-PCR using a specific 
primer set. Expression of beta-actin is served as a standard. On the top, Myc-tagged sFRP1 
expression is shown by western blotting. (D) Efflux activity was examined in MDA-MB-231 cells 
treated with sFRP1 CM and MDA-MB-231 cells treated with control CM for 7 days. Cells were 
incubated with Hoechst followed by the FACS sorting. The “side population” was 0.77% in the 
cohort treated with control CM, while 0.12% in the cohort treated by sFRP1 CM. (E) RNA 
expression of ABCA2 was examined by microarray analysis. The sample order from left to right is 
the same as shown in (A).   
 
Figure 11 
Integrin β1 expression is suppressed upon ectopic sFRP1 expression 
Left: RNA expression level of Integrin β1 in in vivo tumor lysates and in vitro cultured cells. From 
left to right, RNA from tumor lysates arising from MDA-MB-231/sFRP1-P1, tumor lysates arising 
from MDA-MB-231/control-P1, cultured MDA-MB-231/sFRP1-P1 cells and cultured 
MDA-MB-231/control-P1 cells. Right: Integrin β1 positive cells are sorted by FACS analysis using 
the specific antiserum. Experiment is tripricated. sFRP1: MDA-MB-231/sFRP1-P1 cells, control: 
MDA-MB-231/control-P1 cells. Y-axis indicates the proportion of Integrin β1 positive cells. 
 
Figure 12 
P-cadherin expression was promoted by Wnt1 
(A) CDH3 (gene encoding P-cadherin) RNA level in Wnt1 expressing T47D and control T47D cells 
was analyzed by microarray analysis. (B) P-cadherin expression level was analyzed in T47D/Wnt1, 
T47D/Wnt5a and T47D/control pools by western blotting. Three independent pools were made for 
each -/Wnt1, -/Wnt5a and -/control cells (pool#1-pool#3). Each pools consist of more than 100 
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clones. Cells were let to become confluent (left) or 20-30% confluent (right) and lysed. P-cadherin 
was detected by western blotting. α-tubulin serves as a standard. (C) P-cadherin expression level 
shown in (B) was quantified using Odyssey. Y-axsis represents the P-cadherin level normalized by 
α-tubulin level. (D) Ectopically sFRP1 expressing T47D cell pools were established (pool#1 and 
pool#2). Each pool constitutes of more than 100 clones. P-cadherin level was examined by western 
blotting using the specific antiserum. Ectopically expressed Myc-tagged sFRP1 is also detected 
using an anti Myc antibody. α-tubulin serves as a standard. 
    
Supplemental Figure 1 
Proliferation suppression of MDA-MB-231 cells by sFRP1 CM treatment  
One thousand MDA-MB-231 cells were seeded per well of a 96-well plate and proliferation was 
measured with a YOPRO assay after 3 days of treatment with sFRP1 CM or control CM.  
 
Supplemental Figure 2 
Two additional xenograft experiments  
Onset of tumor appearance in two additional xenograft experiments with MDA-MB-231/sFRP1-P1 
and MDA-MB-231/control-P1 cells. Left; 6 mice per group, p=0.0179 (log rank test)   Right; 8 
mice per group, p=0.0223 (log rank test) 
 
Supplemental Figure 3 
Effect of ectopic c-Myc on MDA-MB-231/sFRP1 xenograft growth 
(A) Lysates from MDA-MB-231/sFRP1-P1 cells infected with a c-Myc encoding vector and a 
control vector were analyzed for c-Myc levels with a specific antiserum. (B) 2x105 
MDA-MB-231/sFRP1/Myc and MDA-MB-231/sFRP1/control cells were seeded on 6-well plates 
and cell numbers were counted after 3 days and 4 days. 3 wells per condition. Average cell numbers 
were calculated +/-SEM. n.s.=not significant (C) 1x106 MDA-MB-231/sFRP1/Myc cells and 
MDA-MB-231/sFRP1/control cells were injected into the fat pads of 6 nude mice. 2 of 6 mice 
injected with MDA-MB-231/sFRP1/Myc cells formed tumors on day 26 and on day 41 respectively, 
whereas no mice injected with MDA-MB-231/sFRP1/control cells formed tumors.  p=0.138 (log 
rank test) 
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Supplemental Figure 4 
Ingenuity Pathway Analysis  
(A) Using Affymetrix U133 plus 2.0 human GeneChips™ and the software Genedata’s Analyst 4.5, 
1753 probesets whose levels were changed more than 1.5 fold between sFRP1 positive tumors and 
control tumors with the p-values less than 0.01 using 1-way ANOVA were identified in the 
microarray analysis. These 1753 probes were further analyzed using Ingenuity’s Pathway Analysis 
to identify bio functions most likely to be affected by ectopic sFRP1 expression in the 
MDA-MB-231 xenograft model. The top 10 candidate bio functions (and diseases) are listed, with 
the Fisher’s p-values. (B) In the bio function “cancer”, the sub-category “tumorigenesis” had the 
lowest p-value. 266 genes listed here are related to the “tumorigenesis” bio function. Genes with red 
arrows and green arrows were up-regulated and down-regulated, respectively, upon ectopic sFRP1 
expression in the xenograft tumors. The cut off for all genes was 1.5 fold. 
 
Supplemental Figure 5 
Known WNT target genes whose expression was downregulated upon sFRP1 expression both 
in vitro and in vivo 
Normalized microarray results of established WNT pathway target genes listed in Supplemental 
Table 2  
 
Supplemental Figure 6 
Expression of basal and luminal keratins  
Normalized microarray results of keratin (KRT) 5, 14, 17, 18 and 8 
 
Supplemental Figure 7 
Expression of vimentin and fibronectin 1  
Normalized microarray results of vimentin (VIM) and fibronectin 1 (FN1) 
 
Supplemental Table 1 
List of genes whose expression was altered upon sFRP1 expression only in vivo  
List of 106 (table 1A) and 62 (table 1B) identified genes shown in Fig 7A and 7B, respectively. 
Fold-change (down- or up-regulation) refers to expression changes between sFRP1+ and control 
tumors.  Some genes have more than one probesets with different values of fold-change.    
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Supplemental Table 2 
Established WNT pathway target genes whose expression was suppressed upon sFRP1 
expression both in vitro and in vivo 
Expressions of established WNT pathway target genes 
(http://www.stanford.edu/~rnusse/pathways/targets.html) were examined by microarray analysis. 
Listed here are genes whose expression was suppressed upon sFRP1 expression both in vitro and in 
vivo. 
 
VII. MATERIALS AND METHODS 
Reagents 
The following primary antibodies were used: RhoA (sc-418), c-Myc (9E10), DVL2 and –3 (Santa 
Cruz Biotechnology, Inc., CA, USA); Wnt1 and DVL1 (R&D, Abingdon, UK); active beta-catenin 
(anti-ABC, Upstate, VA, USA); α-tubulin (DM1A) (Neomarkers, CA, USA); Cyclin D1 (SP4) (Cell 
MARQUE, CA, USA) for immunohistochemistry (IHC); Cyclin D1 (Chemicon, MA, USA) for 
western blotting; BrdU (Roche, Basel Switzerland); p21cip1 (OP64-100UG) (Oncogene Research 
Products, MA, USA); ERK and P-ERK (Thr202/Tyr204) (Cell Signaling Technology, MA, USA); 
and CD31 (BD Pharmingen, CA, USA); Integrin β1 (MAB2079Z, chemicon). As secondary 
antibodies we used: anti-rabbit and anti-mouse (GE Healthcare, Little Chalfont Buckinghamshire, 
UK; LI-COR Bioscience, NE, USA), anti-rat (GE Healthcare) or anti-goat (DAKO A/S, Glostrup, 
Denmark) coupled to horse raddish peroxidase (HRP) or IRDye 800CW. For IHC we used: 
Biotin-SP-conjugated affinipure donkey anti-rabbit, anti-mouse, anti-rat IgG (Jackson 
ImmunoResearch, PA, USA), goat anti-rat ALEXA 568 (Molecular probes, OR, USA) and  
TRITC- labelled phalloidin (Sigma, MO, USA). 
Mouse Wnt1 in the retroviral vector pLNCX was obtained from Andrew McMahon (Harvard 
University, Cambridge, MA, USA); the cDNA encoding Myc/His-tagged human sFRP1 in pCDNA 
was provided by Jeffrey Rubin (NCI, Bethesda, MD, USA) and was recloned into the pBabePuro 
retroviral vector: Human c-Myc from c-Myc/pCDNA3Neo [189] was recloned in pBabePuro. 
Conditioned media (CM) from Wnt1 and sFRP1 producing cells, and purified sFRP1 were prepared 
as previously described [177]. 
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Cell culture, transfections, retroviral infections and proliferation assays 
The human breast cancer cell lines, T47D and MDA-MB-231 (ATCC, VA, USA) were cultivated in 
DMEM, 10% heat inactivated FCS (Amimed, Allschwil, Switzerland) supplemented with Penicillin 
and Streptomycin (Sigma). All transfections were performed using FuGENE 6 Transfection 
Reagent (Roche) following the manufacturer’s guidelines. T47D cells were stably transfected with 
Wnt1 or empty pLNCX as control, followed by selection with 0.5mg/ml G-418 (Life Technologies, 
Inc, MD, USA). A clone expressing high levels of Wnt1, T47D/Wnt1 and a control clone were 
previously described [177]. A pool of >100 T47D/Wnt1 clones (T47D/Wnt1-P1) and a pool of 
control clones (T47D/control-P1) were also generated. MDA-MB-231 cells were stably transfected 
with pCDNA3.1(+) (Invitrogen) encoding Myc/His-tagged human sFRP1 or empty pCDNA3.1(+) 
as control. After selection with 1mg/ml G-418, three clones of MDA-MB-231/sFRP1 and three 
control clones were isolated. Equal cell numbers of these clones were pooled before some 
experiments (MDA-MB-231/sFRP1-P1 and MDA-MB-231/control-P1). A second pool of sFRP1 
expressing MDA-MB-231 cells (MDA-MB-231/sFRP1-P2) and control cells 
(MDA-MB-231/control-P2), each representing >100 clones, was generated by infecting the cells 
with pBabePuro encoding Myc/His-tagged human sFRP1 or empty pBabePuro followed by the 
selection with 2 µg/ml Puromycin (Sigma). For the c-Myc rescue experiment, 
MDA-MB-231/sFRP1-P1 cells were infected with a pBabePuro vector encoding human c-Myc or 
empty pBabePuro as control. These cells were selected with 1mg/ml G-418 and 2µg/ml Puromycin 
and pooled to make MDA-MB-231/sFRP1/Myc and MDA-MB-231/sFRP1/control. Cell 
proliferation was measured either by counting cell numbers with a Vi-Cell XR cell viability 
analyzer (Beckman Coulter, CA, USA) on selected days after seeding 200000 cells on 6-well plates 
or using the YOPRO cell viability assay (Invitrogen) 3 days after seeding 1000 cells on 96-well 
plate, according to manufacturer’s instructions. Unless otherwise noted, p-values were calculated 
using Student’s t-test. 
 
Protein extraction and western blotting 
Cells were lysed in 1% Nonidet P-40, 50mM Tris pH 7.5, 120mM NaCl, 5mM EDTA, 1mM EGTA, 
2mM sodium vanadate, 20mM β-glycerophosphate, 10µg/ml aprotinin, 10µg/ml leupeptin, 0.5mM 
PMSF, 50mM NaF, 1mM DTT for 5min on ice before collecting lysates. Debris was removed by 
centrifugation at 4°C and protein concentration was determined using the Bradford reagent (BioRad, 
CA, USA). For western blotting, protein loading buffer was added to 30-50µg of total protein and 
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the samples were denatured for 10min at 95°C prior to separation on SDS-polyacrylamide gels and 
blotting by semi-dry transfer for 90min on PVDF membrane (Millipore, MA, USA). Membranes 
were blocked using 10% horse serum in TBS-T buffer for 1h (0.2M NaCl, 25mM Tris, pH 7.5, 
0.5mL/L Tween-20), except for p21Cip detection where PBS-T buffer was used for blocking. Blots 
were incubated with primary antibodies at room temperature for 1h or at 4°C overnight, followed by 
a 30 min incubation with secondary antibodies anti-rabbit-, anti-mouse-HRP (1:5000) or 
anti-goat-HRP (1:5000) either IRDye 800CW Goat anti-rabbit- or anti-mouse-IgG (1:10000) 
(LI-COR Biosciences). Detection of luminescence was carried out using ECL (GE Healthcare) 
according to manufacturer’s instructions and using X-OMAT LS films (Kodak, NY, USA), or 
performed using the LI-COR Odyssey system according to manufacturer`s instructions (LI-COR 
Biosciences). Quantification of protein expression was done using Odyssey 2.1 (LI-COR 
Biosciences). 
 
Immunofluorescence microscopy 
Cells were seeded on glass coverslips (BD Biosciences, CA, USA) in DMEM 10% FCS. 30 minutes 
after media was changed to Wnt1 CM or control CM, cells were fixed with 4 % paraformaldehyde 
and 3 % sucrose in PBS, permeabilized in 0.2% Triton X-100 in PBS, and blocked with 10% goat 
serum in PBS. F-actin was stained at RT with 2 U/ml TRITC-labelled phalloidin (Sigma). Cells 
were washed with PBS and mounted with a mounting solution (Calbiochem, CA, USA). Mounted 
samples were examined using an LSM510 microscope (Carl Zeiss, Jena, Germany). 
 
Wound healing assay 
Cells were seeded on 6-well plates and grown to confluency. Monolayers were scratched, and in the 
indicated experiments media was changed to Wnt1 CM or control CM. Pictures of randomly-chosen 
9 wound edges per condition were taken at time 0 and at indicated time points using Nikon 
DIAPHOT (Nikon, Tokyo, Japan). Recovered area was calculated using ImageQuant TL (GE 
Healthcare). In some experiments, purified sFRP1 [177] was added to the CM.  
 
RhoA activity assay 
Active RhoA was detected using a glutathione S-transferase (GST) −C21 (Rhotekin) fusion protein, 
as described previously [290]. Briefly, lysates from cells were incubated with bacterially produced 
GST−C21 fusion protein bound to glutathione−Sepharose beads. Proteins bound to the fusion 
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protein were analysed by western blotting using an anti-RhoA antibody (Santa Cruz). Aliquots from 
the cell lysates were taken to analyse total RhoA levels. 
 
MDA-MB-231 xenograft model, BrdU incorporation and tumor lysis  
7-10 weeks old female Balb/c nude mice were obtained from Charles River Laboratories 
(L’Arbresle, France) and were maintained in accordance with the Swiss guidelines for animal safely. 
Mammary tumors were established in the mice by injecting 0.5-1.0 x 106 control or sFRP1 
expressing MDA-MB-231 cells either appropriate cell lines in 100-150 µl PBS into the fourth 
right-side mammary fat pads of 5-8 mice per group. Tumor size was measured 2-3 times a week 
using a gage and the volume was calculated considering a tumor as a oval according to the formula, 
4π(longer edge/2)(shorter edge/2)2/3. To assay tumor cell proliferation in vivo, mice were injected in 
the abdomen (Intraperitoneal injection) with 100µg/g body weight BrdU (Cell Proliferation Kit II, 
Roche) and sacrificed 2h later. Tumors were excised and washed with PBS before fixation in 4% 
PFA at 4°C for 24 hours. Procedures for detection of BrdU were performed as previously described 
[273]. Excised tumors were snap frozen and pulverized in liquid nitrogen and lysed in SDS buffer 
(100mM Tris-HCl pH 7.6, 2% SDS, 10mM DTT, 2mM sodium vanadate, 0.5mM EDTA) by 
incubation at 95°C for 10 min. Western blot analyses were carried out to detect specific proteins.  
 
RNA isolation, quantitative RT-PCR and semi-quantitative RT-PCR  
Cultured cells were collected when plates were 70-80% confluent and RNA was extracted using 
RNeasy Mini kit (Qiagen, Venlo, The Netherlands). To extract the RNA from tumours, dissected 
tumours were put in RNAlater (Qiagen) over night at 4°C, followed by RNA extraction using 
TRIzol reagent (Invitrogen) and washing using the RNAeasy Mini kit according to manufacturer’s 
instructions. For each sample cDNA was made from 2.5µg of RNA using Ready-To-Go™ 
You-Prime First-Strand Beads (GE healthcare). Semi-quantitative PCR was performed using taq 
DNA polymerase. Quantitative RT-PCR was performed with ABI prism 7000 (Applied Biosystems, 
CA, USA) using ABsolute SYBR Green ROX Mix (THERMO scientific, MA, USA) following the 
manufacturer’s guidelines. Primer sequences used are shown in the end of this section. 
 
Methylation analysis 
Genomic DNA was extracted from the cell lines and detection of the methylated- or unmethylated 
promoter sequence was done using EpiTect Bisulfite Kit (QIAGEN) following manufacturer’s 
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instructions with the primers which are shown in the paper published [193]. Promeer sequences 
used are shown in the end of this section. 
 
Microarray analysis 
Total RNA was isolated from individual mammary tumors (6 MDA-MB-231/sFRP1-P1 tumors and 
5 control tumors) and cultured cells (3 MDA-MB-231/sFRP1 clones and 3 control clones). All 
RNAs were individually amplified and labeled using the Ambion MessageAMP III RNA 
Amplification Kit. Biotinylated, fragmented cRNA was hybridized to Affymetrix U133 plus 2.0 
human GeneChips™ (Affymetrix, CA, USA). Expression values were estimated using the 
GC-RMA implementation found in Genedata’s Refiner 4.5 software (Gendata AG, Basel, 
Switzerland). Quantile normalization and median scaling were performed in order to standardize 
array signal distributions to facilitate the comparison between in vitro cultured cells and in vivo 
tumor samples. Probesets showing statistically different expression profiles (1-way ANOVA with 
p<0.01; Benjamini and Hochberg Q-values were determined to minimize the false discovery rate) 
and specific pairwise fold changes were clustered by rank correlation with an R value of R>0.8 for 
the first criterion and R>0.885 for the second criterion using “Profile Distance Search” function of 
Genedata’s Analyst 4.5 tool. Functional analyses were generated through the use of Ingenuity 
Pathways Analysis (Ingenuity Systems®, www.ingenuity.com). The Bio functional Analysis 
identified the biological functions and diseases that were most significantly enriched within the data 
set. Genes from the dataset that were associated with biological functions and diseases in the 
Ingenuity knowledge base were considered for the analysis.  Fisher’s exact test was used to 
calculate a p-value determining the probability that each biological function and disease assigned to 
that data set is due to chance alone. 
 
The entire set of microarray data is in GEO (Gene Expression Omnibus) with accession number 
GSE13806 (released when paper is published). 
 
Immunohistochemistry and functional vessel analysis on tumor sections 
To detect functional vessels in tumors, 100 µl of a 2 µg/µl solution of Fluorescein-labeled 
Lycopersicon esculentum lectin (Vector Labs, CA, USA) was injected into tail veins of 
tumor-bearing mice [188] and mice were sacrificed 5 min later. Tumors were excised, fixed in 4% 
paraformaldehyde in PBS for 48 h at 4°C, followed by an overnight incubation in 30% sucrose in 
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PBS at 4°C then embedded in tissue-Tec O.C.T. compound 4583 (Sakura, Tokyo, Japan). Frozen 
sections (9 µm) were subjected to IHC analysis to detect tumor-associated vessels using rat 
anti-mouse CD31 (BD Pharmingen; diluted 1:100) and goat anti-rat ALEXA 568 (Molecular 
Probes; diluted 1:200). Staining was done using Discovery XT (Ventana Medical Systems, Inc., AZ, 
USA). Pictures were taken with a Z1 microscope (Carl Zeiss) and analyzed with IMARIS (Bitplane, 
Zurich, Switzerland) to calculate the co-localized area. For detection of Cyclin D1, frozen tumor 
sections (9 µm) were subjected to IHC analysis using the SP4 antibody (diluted 1:100) and 
Biotin-SP-conjugated affinipure donkey anti-rabbit IgG (diluted 1:100). Staining was done using 
Discovery XT with sCC1 pretreatment. Pictures were taken with Eclipse E600 (Nikon) and 
analyzed with IMARIS (Bitplane) to calculate signal intensity.  
 
FACS analysis 
Following the incubation, cells were tripsinized and 3 x 105 cells were re-suspended and incubated 
with 1µg of 1st Ab in 50µl PBS at 4°C for 60 min followed by the 2nd Ab (dilution=1:250). 
Afterwards, cells were washed, pelleted and re-suspended in 300µl FACS buffer and sorted by 
FACS.   
 
Sorting of cancer cell side population 
MDA-MB-231 cells were cultured in sFRP1 CM or in control CM for 7 days. Afterwards, cells 
were tripsinized, pelleted and 106 cells were re-suspended in 1ml DMEM 10% FCS. Hoechst 33342 
dye was added to a final concentration of 5µg/ml and cells were incubated at 37°C in a water bath 
for 60 min. After the incubation, cells were centrifuged at 1500rpm at 4°C, washed with 
PBS/2%FCS and re-suspend in 500-1000µl PBS/2%FCS. Propidium iodide was added prior to 
FACS analyis to a final concentration of 2µg/ml (stock solution 1mg/ml in EtOH). 
 
Primers used for the experiments 
Primers Sequence (5’-3’) experiment 
human sFRP1 forward 
human sFRP1 reverse 
GGTCTTCCTCTGCTCGCTCTTC 
AGGACACACCGTTGTGCCTT 
Quantitative RT-PCR 
 
human Myc forward 
human Myc reverse 
CCTACCCTCTCAACGACAG 
CTTGTTCCTCCTCAGAGTCG 
Quantitative RT-PCR 
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human β-actin forward 
human β-actin reverse 
TGTCCACCTTCCAGCAGATGT 
CGCAACTAAGTCATAGTCCGCC 
Quantitative RT-PCR 
 
sFRP1 unmrthylated forward 
sFRP1 unmrthylated reverse 
TTTTAGTAAATTGAATTTGTTTGTGA 
TAAAATACACAAAACTCCTACAAC 
methylation alanysis 
(Lo et al. 2006) 
sFRP1 mrthylated forward 
sFRP1 mrthylated reverse 
TTTAGTAAATCGAATTCGTTCGC 
TAAAATACGCGAAACTCCTACG 
methylation analysis 
(Lo et al. 2006) 
human SOX2 forward 
human SOX2 reverse 
CCGCATGTACAACATGATGG 
CTTCTTCATGAGCGTCTTGG 
semi-quantitative RT-PCR 
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